Identification

Name
Fluoxetine
Accession Number
DB00472  (APRD00530)
Type
Small Molecule
Groups
Approved, Vet approved
Description

Fluoxetine hydrochloride is the first agent of the class of antidepressants known as selective serotonin-reuptake inhibitors (SSRIs). Fluoxetine is a racemic mixture of the R- and S- enantiomers and are of equivalent pharmacologic activity. Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity. As with other antidepressant agents, several weeks of therapy may be required before a clinical effect is seen. SSRIs are potent inhibitors of neuronal serotonin reuptake. They have little to no effect on norepinephrine or dopamine reuptake and do not antagonize α- or β-adrenergic, dopamine D2 or histamine H1 receptors. During acute use, SSRIs block serotonin reuptake and increase serotonin stimulation of somatodendritic 5-HT1A and terminal autoreceptors. Chronic use leads to desensitization of somatodendritic 5-HT1A and terminal autoreceptors. The overall clinical effect of increased mood and decreased anxiety is thought to be due to adaptive changes in neuronal function that leads to enhanced serotonergic neurotransmission. Side effects include dry mouth, nausea, dizziness, drowsiness, sexual dysfunction and headache. Side effects generally occur within the first two weeks of therapy and are usually less severe and frequent than those observed with tricyclic antidepressants. Fluoxetine may be used to treat major depressive disorder (MDD), moderate to severe bulimia nervosa, obsessive-compulsive disorder (OCD), premenstrual dysphoric disorder (PMDD), panic disorder with or without agoraphobia, and in combination with olanzapine for treatment-resistant or bipolar I depression. Fluoxetine is the most anorexic and stimulating SSRI.

Structure
Thumb
Synonyms
  • (+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-P-tolyl)oxy)propylamine
  • (+-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
  • Fluoxetin
  • Fluoxetina
  • Fluoxétine
  • Fluoxetinum
External IDs
Lilly 103472 / Lilly 110 140
Product Ingredients
IngredientUNIICASInChI Key
Fluoxetine HydrochlorideI9W7N6B1KJ56296-78-7GIYXAJPCNFJEHY-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act FluoxetineCapsule10 mgOralDr Reddy's Laboratories2000-05-31Not applicableCanada
Act FluoxetineCapsule40 mgOralDr Reddy's LaboratoriesNot applicableNot applicableCanada
Act FluoxetineCapsule20 mgOralDr Reddy's Laboratories2000-05-31Not applicableCanada
Bci FluoxetineCapsule20 mgOralBaker Cummins IncNot applicableNot applicableCanada
FluoxetineCapsule10 mgOralMeliapharm Inc2010-06-112014-06-25Canada
FluoxetineCapsule20 mgOralSivem Pharmaceuticals Ulc2011-10-14Not applicableCanada
FluoxetineCapsule20 mgOralSanis Health Inc2009-10-22Not applicableCanada
FluoxetineCapsule10 mgOralSanis Health Inc2009-10-22Not applicableCanada
FluoxetineCapsule10 mgOralSivem Pharmaceuticals Ulc2011-10-14Not applicableCanada
FluoxetineCapsule20 mgOralMeliapharm Inc2010-06-112014-06-25Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Accel-fluoxetineCapsule20 mgOralAccel Pharma Inc2015-03-26Not applicableCanada
Accel-fluoxetineCapsule10 mgOralAccel Pharma Inc2015-03-26Not applicableCanada
Ach-fluoxetineCapsule10 mgOralAccord Healthcare Limited2012-10-10Not applicableCanada
Ach-fluoxetineCapsule20 mgOralAccord Healthcare Limited2012-05-01Not applicableCanada
Apo-fluoxetineCapsule20 mgOralApotex Corporation1996-12-31Not applicableCanada
Apo-fluoxetineSolution20 mgOralApotex Corporation1997-06-16Not applicableCanada
Apo-fluoxetineCapsule10 mgOralApotex Corporation1996-12-31Not applicableCanada
Auro-fluoxetineCapsule10 mgOralAuro Pharma Inc2012-07-24Not applicableCanada
Auro-fluoxetineCapsule20 mgOralAuro Pharma Inc2012-07-24Not applicableCanada
Ava-fluoxetineCapsule20 mgOralAvanstra Inc2011-11-282014-08-21Canada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Olanzapine and FluoxetineFluoxetine Hydrochloride (25 mg/1) + Olanzapine (12 mg/1)CapsuleOralTeva2012-06-19Not applicableUs
Olanzapine and FluoxetineFluoxetine Hydrochloride (25 mg/1) + Olanzapine (3 mg/1)CapsuleOralAv Kare, Inc.2014-01-21Not applicableUs
Olanzapine and FluoxetineFluoxetine Hydrochloride (50 mg/1) + Olanzapine (6 mg/1)CapsuleOralPar Pharmaceutical2012-11-26Not applicableUs
Olanzapine and FluoxetineFluoxetine Hydrochloride (50 mg/1) + Olanzapine (12 mg/1)CapsuleOralSandoz2012-11-30Not applicableUs
Olanzapine and FluoxetineFluoxetine Hydrochloride (25 mg/1) + Olanzapine (3 mg/1)CapsuleOralTeva2013-04-10Not applicableUs00093 5503 56 nlmimage10 a8365432
Olanzapine and FluoxetineFluoxetine Hydrochloride (25 mg/1) + Olanzapine (6 mg/1)CapsuleOralSandoz2012-11-30Not applicableUs
Olanzapine and FluoxetineFluoxetine Hydrochloride (50 mg/1) + Olanzapine (6 mg/1)CapsuleOralAv Kare, Inc.2014-01-21Not applicableUs00093 5505 56 nlmimage10 f426fa17
Olanzapine and FluoxetineFluoxetine Hydrochloride (50 mg/1) + Olanzapine (12 mg/1)CapsuleOralPar Pharmaceutical2012-11-26Not applicableUs
Olanzapine and FluoxetineFluoxetine Hydrochloride (25 mg/1) + Olanzapine (6 mg/1)CapsuleOralPar Pharmaceutical2012-11-26Not applicableUs
Olanzapine and FluoxetineFluoxetine Hydrochloride (50 mg/1) + Olanzapine (12 mg/1)CapsuleOralAv Kare, Inc.2014-01-21Not applicableUs00093 5507 56 nlmimage10 0c270618
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
GaboxetineFluoxetine Hydrochloride + CholineKitPhysician Therapeutics Llc2011-07-072016-10-13Us
Sentraflox AM-10Fluoxetine Hydrochloride + CholineKitPhysician Therapeutics Llc2011-07-072016-10-13Us
SentroxatineFluoxetine Hydrochloride + CholineKitPhysician Therapeutics Llc2011-02-172016-10-13Us
International/Other Brands
Adofen (Brainpharma) / Animex-On (Laboratorios) / Fluoxeren (Menarini) / Fontex (Lilly) / Ladose (Lilly) / Prozac
Categories
UNII
01K63SUP8D
CAS number
54910-89-3
Weight
Average: 309.3261
Monoisotopic: 309.134048818
Chemical Formula
C17H18F3NO
InChI Key
RTHCYVBBDHJXIQ-UHFFFAOYSA-N
InChI
InChI=1S/C17H18F3NO/c1-21-12-11-16(13-5-3-2-4-6-13)22-15-9-7-14(8-10-15)17(18,19)20/h2-10,16,21H,11-12H2,1H3
IUPAC Name
methyl({3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl})amine
SMILES
CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1

Pharmacology

Indication

Labeled indication include: major depressive disorder (MDD), moderate to severe bulimia nervosa, obsessive-compulsive disorder (OCD), premenstrual dysphoric disorder (PMDD), panic disorder with or without agoraphobia, and combination treatment with olanzapine for treatment-resistant or bipolar I depression. Unlabeled indications include: selective mutism, mild dementia-associated agitation in nonpsychotic patients, post-traumatic stress disorder (PTSD), social anxiety disorder, chronic neuropathic pain, fibromyalgia, and Raynaud's phenomenon.

Associated Conditions
Pharmacodynamics

Fluoxetine, an antidepressant agent belonging to the selective serotonin reuptake inhibitors (SSRIs), is used to treat depression, bulimia nervosa, premenstrual dysphoric disorder, panic disorder and post-traumatic stress. According to the amines hypothesis, a functional decrease in the activity of amines, such as serotonin and norepinephrine, would result in depression; a functional increase of the activity of these amines would result in mood elevation. Fluoxetine's effects are thought to be associated with the inhibition of 5HT receptor, which leads to an increase of serotonin level. Antagonism of muscarinic, histaminergic, and α1–adrenergic receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular effects of classical tricyclic antidepressant (TCA) drugs. Fluoxetine binds to these and other membrane receptors from brain tissue much less potently in vitro than do the tricyclic drugs.

Mechanism of action

Metabolized to norfluoxetine, fluoxetine is a selective serotonin-reuptake inhibitor (SSRI), it blocks the reuptake of serotonin at the serotonin reuptake pump of the neuronal membrane, enhancing the actions of serotonin on 5HT1A autoreceptors. SSRIs bind with significantly less affinity to histamine, acetylcholine, and norepinephrine receptors than tricyclic antidepressant drugs.

TargetActionsOrganism
ASodium-dependent serotonin transporter
inhibitor
Human
UPotassium voltage-gated channel subfamily H member 2
inhibitor
Human
U5-hydroxytryptamine receptor 2C
antagonist
Human
UCyclin-dependent kinases regulatory subunit 1Not AvailableHuman
UNeuronal acetylcholine receptor subunit alpha-2
antagonist
Human
UNeuronal acetylcholine receptor subunit alpha-3
antagonist
Human
UNeuronal acetylcholine receptor subunit beta-4
antagonist
Human
Absorption

Well absorbed from the GI tract following oral administration. Oral bioavailability is estimated to be at least 60-80%. Peak plasma concentrations occur within 6-8 hours following a single oral administration of a 40 mg dose. The oral solution and delayed-release capsule are bioequivalent. Food does not affect the systemic bioavailability of fluoxetine but it delays the absorption by 1-2 hours (not clinically significant). Prozac Weekly capsules, a delayed–release formulation, contain enteric–coated pellets that resist dissolution until reaching a segment of the gastrointestinal tract where the pH exceeds 5.5. The enteric coating delays the onset of absorption of fluoxetine 1 to 2 hours relative to the immediate–release formulations.

Volume of distribution
  • 20-45 L/kg
Protein binding

94.5% bound to human serum proteins, including albumin and alpha-1-glycoprotein.

Metabolism

Limited data from animal studies suggest that fluoxetine may undergo first-pass metabolism may occur via the liver and/or lungs. Fluoxetine appears to be extensively metabolized, likely in the liver, to norfluoxetine and other metabolites. Norfluoxetine, the principal active metabolite, is formed via N-demethylation of fluoxetine. Norfluoxetine appears to be comparable pharmacologic potency as fluoxetine. Fluoxetine and norfluoxetine both undergo phase II glucuronidation reactions in the liver. It is also thought that fluoxetine and norfluoxetine undergo O-dealkylation to form p-trifluoromethylphenol, which is then subsequently metabolized to hippuric acid.

Route of elimination

The primary route of elimination appears to be hepatic metabolism to inactive metabolites excreted by the kidney. The S-enantiomer is eliminated more slowly and is the predominant enantiomer present at steady state.

Half life

1-3 days [acute administration]; 4-6 days [chronic administration]; 4-16 days [norfluoxetine, acute and chronic administration].

Clearance
Not Available
Toxicity

Symptoms of overdose include agitation, restlessness, hypomania, and other signs of CNS excitation. LD50=284mg/kg (orally in mice). The most frequent side effects include: nervous system effects such as anxiety, nervousness, insomnia, drowsiness, fatigue or asthenia, tremor, and dizziness or lightheadedness; GI effects such as anorexia, nausea, and diarrhea; vasodilation; dry mouth; abnormal vision; decreased libido; abnormal ejaculation; rash; and sweating. Withdrawal symptoms include flu-like symptoms, insomnia, nausea, imbalance, sensory changes and hyperactivity.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Fluoxetine Action PathwayDrug action
Fluoxetine Metabolism PathwayDrug metabolism
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(2-benzhydryloxyethyl)diethyl-methylammonium iodideThe risk or severity of adverse effects can be increased when (2-benzhydryloxyethyl)diethyl-methylammonium iodide is combined with Fluoxetine.Experimental
(R)-warfarinFluoxetine may increase the antiplatelet activities of (R)-warfarin.Experimental
(S)-WarfarinFluoxetine may increase the antiplatelet activities of (S)-Warfarin.Experimental, Investigational
1,10-PhenanthrolineThe therapeutic efficacy of Fluoxetine can be decreased when used in combination with 1,10-Phenanthroline.Experimental
2,4-thiazolidinedioneFluoxetine may increase the hypoglycemic activities of 2,4-thiazolidinedione.Investigational
3,4-MethylenedioxyamphetamineThe risk or severity of adverse effects can be increased when 3,4-Methylenedioxyamphetamine is combined with Fluoxetine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Fluoxetine.Experimental, Illicit
4-hydroxycoumarinFluoxetine may increase the antiplatelet activities of 4-hydroxycoumarin.Experimental
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Methoxyamphetamine is combined with Fluoxetine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Fluoxetine.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Fluoxetine.Experimental
AbciximabFluoxetine may increase the antiplatelet activities of Abciximab.Approved
AbemaciclibThe serum concentration of Abemaciclib can be increased when it is combined with Fluoxetine.Approved, Investigational
AbexinostatThe risk or severity of QTc prolongation can be increased when Abexinostat is combined with Fluoxetine.Investigational
AbirateroneThe serum concentration of Fluoxetine can be increased when it is combined with Abiraterone.Approved
AcarboseFluoxetine may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Fluoxetine.Approved, Investigational
AceclofenacFluoxetine may increase the antiplatelet activities of Aceclofenac.Approved, Investigational
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Fluoxetine.Approved, Investigational
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Fluoxetine.Approved, Vet Approved
AceprometazineThe risk or severity of QTc prolongation can be increased when Aceprometazine is combined with Fluoxetine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Fluoxetine.Approved, Vet Approved
AcetohexamideFluoxetine may increase the hypoglycemic activities of Acetohexamide.Approved, Investigational, Withdrawn
AcetophenazineThe risk or severity of adverse effects can be increased when Acetophenazine is combined with Fluoxetine.Approved
Acetylglycinamide chloral hydrateThe risk or severity of adverse effects can be increased when Acetylglycinamide chloral hydrate is combined with Fluoxetine.Experimental
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Fluoxetine.Approved
AcrivastineThe risk or severity of QTc prolongation can be increased when Acrivastine is combined with Fluoxetine.Approved
AdinazolamThe risk or severity of adverse effects can be increased when Adinazolam is combined with Fluoxetine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Fluoxetine.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Fluoxetine.Approved
AgmatineThe risk or severity of adverse effects can be increased when Agmatine is combined with Fluoxetine.Experimental, Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Fluoxetine.Approved, Investigational
AICA ribonucleotideFluoxetine may increase the hypoglycemic activities of AICA ribonucleotide.Experimental, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Alaproclate.Experimental
AlbiglutideFluoxetine may increase the hypoglycemic activities of Albiglutide.Approved
AlcaftadineThe risk or severity of QTc prolongation can be increased when Alcaftadine is combined with Fluoxetine.Approved
AlcuroniumThe risk or severity of adverse effects can be increased when Alcuronium is combined with Fluoxetine.Experimental
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Fluoxetine.Experimental, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Fluoxetine.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Fluoxetine.Approved, Illicit
AlfuzosinThe risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Fluoxetine.Approved, Investigational
AlimemazineThe risk or severity of QTc prolongation can be increased when Alimemazine is combined with Fluoxetine.Approved, Vet Approved
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Fluoxetine.Approved, Investigational
AllobarbitalThe risk or severity of adverse effects can be increased when Allobarbital is combined with Fluoxetine.Experimental
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Fluoxetine.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Almotriptan.Approved, Investigational
AlogliptinFluoxetine may increase the hypoglycemic activities of Alogliptin.Approved
AlosetronAlosetron may increase the serotonergic activities of Fluoxetine.Approved, Withdrawn
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Fluoxetine.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Fluoxetine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Fluoxetine.Approved, Illicit, Investigational
AlprenololThe serum concentration of Alprenolol can be increased when it is combined with Fluoxetine.Approved, Withdrawn
AlteplaseFluoxetine may increase the antiplatelet activities of Alteplase.Approved
AmantadineThe risk or severity of QTc prolongation can be increased when Amantadine is combined with Fluoxetine.Approved
AmbenoniumThe therapeutic efficacy of Fluoxetine can be decreased when used in combination with Ambenonium.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Fluoxetine.Approved, Investigational
AmediplaseFluoxetine may increase the antiplatelet activities of Amediplase.Investigational
AMG-222Fluoxetine may increase the hypoglycemic activities of AMG-222.Investigational
AmifampridineThe risk or severity of QTc prolongation can be increased when Amifampridine is combined with Fluoxetine.Approved
AmikacinThe risk or severity of adverse effects can be increased when Amikacin is combined with Fluoxetine.Approved, Investigational, Vet Approved
AmineptineThe risk or severity of adverse effects can be increased when Amineptine is combined with Fluoxetine.Illicit, Withdrawn
AmiodaroneThe risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Fluoxetine.Approved, Investigational
AmitriptylineThe risk or severity of QTc prolongation can be increased when Amitriptyline is combined with Fluoxetine.Approved
AmitriptylinoxideThe risk or severity of adverse effects can be increased when Amitriptylinoxide is combined with Fluoxetine.Approved, Investigational
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Fluoxetine.Approved, Illicit
AmodiaquineThe risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Fluoxetine.Approved, Investigational
AmoxapineThe risk or severity of QTc prolongation can be increased when Amoxapine is combined with Fluoxetine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Fluoxetine.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Fluoxetine.Approved, Illicit, Investigational
AmprenavirThe serum concentration of Amprenavir can be increased when it is combined with Fluoxetine.Approved, Investigational
AnagliptinFluoxetine may increase the hypoglycemic activities of Anagliptin.Investigational
AnagrelideThe risk or severity of QTc prolongation can be increased when Anagrelide is combined with Fluoxetine.Approved
AncrodFluoxetine may increase the antiplatelet activities of Ancrod.Approved, Investigational
AndrographolideFluoxetine may increase the antiplatelet activities of Andrographolide.Investigational
AniracetamThe risk or severity of adverse effects can be increased when Aniracetam is combined with Fluoxetine.Experimental
AnisodamineThe serum concentration of Anisodamine can be increased when it is combined with Fluoxetine.Investigational
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Fluoxetine.Approved
AnistreplaseFluoxetine may increase the antiplatelet activities of Anistreplase.Approved
AntazolineThe risk or severity of QTc prolongation can be increased when Antazoline is combined with Fluoxetine.Approved
AntipyrineFluoxetine may increase the antiplatelet activities of Antipyrine.Approved, Investigational
Antithrombin III humanFluoxetine may increase the antiplatelet activities of Antithrombin III human.Approved
AntrafenineFluoxetine may increase the antiplatelet activities of Antrafenine.Approved
ApalutamideThe serum concentration of Fluoxetine can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanThe metabolism of Apixaban can be decreased when combined with Fluoxetine.Approved
ApomorphineThe risk or severity of QTc prolongation can be increased when Apomorphine is combined with Fluoxetine.Approved, Investigational
ApramycinThe risk or severity of adverse effects can be increased when Apramycin is combined with Fluoxetine.Experimental, Vet Approved
AprepitantThe serum concentration of Fluoxetine can be increased when it is combined with Aprepitant.Approved, Investigational
AprobarbitalThe risk or severity of adverse effects can be increased when Aprobarbital is combined with Fluoxetine.Approved, Illicit
ApronalideThe risk or severity of adverse effects can be increased when Apronalide is combined with Fluoxetine.Experimental
Arbaclofen PlacarbilThe risk or severity of adverse effects can be increased when Arbaclofen Placarbil is combined with Fluoxetine.Investigational
ArbekacinThe risk or severity of adverse effects can be increased when Arbekacin is combined with Fluoxetine.Approved, Investigational
ArdeparinFluoxetine may increase the antiplatelet activities of Ardeparin.Approved, Investigational, Withdrawn
ArformoterolThe risk or severity of QTc prolongation can be increased when Arformoterol is combined with Fluoxetine.Approved, Investigational
ArgatrobanFluoxetine may increase the antiplatelet activities of Argatroban.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Aripiprazole.Approved, Investigational
Aripiprazole lauroxilThe serum concentration of aripiprazole, an active metabolite of Fluoxetine, can be increased when used in combination with Aripiprazole lauroxil.Approved, Investigational
ArotinololThe serum concentration of Arotinolol can be increased when it is combined with Fluoxetine.Investigational
Arsenic trioxideThe risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Arsenic trioxide.Approved, Investigational
ArtemetherThe risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Artemether.Approved
Ascorbic acidThe serum concentration of Ascorbic acid can be increased when it is combined with Fluoxetine.Approved, Nutraceutical
AsenapineThe risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Asenapine.Approved
AstaxanthinFluoxetine may increase the antiplatelet activities of Astaxanthin.Investigational
AstemizoleThe risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Astemizole.Approved, Withdrawn
AsunaprevirThe serum concentration of Asunaprevir can be increased when it is combined with Fluoxetine.Approved, Investigational, Withdrawn
AtazanavirThe risk or severity of QTc prolongation can be increased when Atazanavir is combined with Fluoxetine.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Fluoxetine.Approved
AtomoxetineThe serum concentration of Atomoxetine can be increased when it is combined with Fluoxetine.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Fluoxetine.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Atracurium is combined with Fluoxetine.Approved, Experimental, Investigational
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Fluoxetine.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Fluoxetine.Approved, Vet Approved
AvatrombopagThe serum concentration of Avatrombopag can be increased when it is combined with Fluoxetine.Approved, Investigational
AxitinibThe metabolism of Axitinib can be decreased when combined with Fluoxetine.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Fluoxetine.Investigational, Vet Approved
AzatadineThe risk or severity of QTc prolongation can be increased when Azatadine is combined with Fluoxetine.Approved
AZD-3043The risk or severity of adverse effects can be increased when AZD-3043 is combined with Fluoxetine.Investigational
AzelastineFluoxetine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzithromycinThe risk or severity of QTc prolongation can be increased when Azithromycin is combined with Fluoxetine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Fluoxetine.Approved
BalaglitazoneFluoxetine may increase the hypoglycemic activities of Balaglitazone.Investigational
BalsalazideFluoxetine may increase the antiplatelet activities of Balsalazide.Approved, Investigational
BarbexacloneThe risk or severity of adverse effects can be increased when Barbexaclone is combined with Fluoxetine.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Fluoxetine.Illicit
Barbituric acid derivativeThe risk or severity of adverse effects can be increased when Barbituric acid derivative is combined with Fluoxetine.Experimental, Illicit
BaricitinibThe serum concentration of Baricitinib can be increased when it is combined with Fluoxetine.Approved, Investigational
BeclamideThe risk or severity of adverse effects can be increased when Beclamide is combined with Fluoxetine.Experimental
BedaquilineThe risk or severity of QTc prolongation can be increased when Bedaquiline is combined with Fluoxetine.Approved
BefunololThe serum concentration of Befunolol can be increased when it is combined with Fluoxetine.Experimental
BekanamycinThe risk or severity of adverse effects can be increased when Bekanamycin is combined with Fluoxetine.Experimental
BelinostatThe serum concentration of Belinostat can be increased when it is combined with Fluoxetine.Approved, Investigational
BemiparinFluoxetine may increase the antiplatelet activities of Bemiparin.Approved, Investigational
Bempedoic acidFluoxetine may increase the hypoglycemic activities of Bempedoic acid.Investigational
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Fluoxetine.Withdrawn
BendroflumethiazideThe risk or severity of hyponatremia can be increased when Fluoxetine is combined with Bendroflumethiazide.Approved
BenfluorexFluoxetine may increase the hypoglycemic activities of Benfluorex.Investigational, Withdrawn
BenmoxinBenmoxin may increase the serotonergic activities of Fluoxetine.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with Fluoxetine.Approved, Investigational
BenzatropineThe risk or severity of QTc prolongation can be increased when Benzatropine is combined with Fluoxetine.Approved
BenziloneThe risk or severity of adverse effects can be increased when Benzilone is combined with Fluoxetine.Experimental
BenzoctamineThe risk or severity of adverse effects can be increased when Benzoctamine is combined with Fluoxetine.Approved
BenzphetamineThe risk or severity of serotonin syndrome can be increased when Fluoxetine is combined with Benzphetamine.Approved, Illicit
BenzquinamideThe risk or severity of adverse effects can be increased when Benzquinamide is combined with Fluoxetine.Withdrawn
BenzthiazideThe risk or severity of hyponatremia can be increased when Fluoxetine is combined with Benzthiazide.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Fluoxetine.Approved
BepridilThe risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Bepridil.Approved, Withdrawn
BeraprostFluoxetine may increase the antiplatelet activities of Beraprost.Investigational
BesifloxacinThe risk or severity of QTc prolongation can be increased when Besifloxacin is combined with Fluoxetine.Approved
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Fluoxetine.Approved, Vet Approved
BetaxololThe serum concentration of Betaxolol can be increased when it is combined with Fluoxetine.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Fluoxetine.Approved, Investigational
BevantololThe serum concentration of Bevantolol can be increased when it is combined with Fluoxetine.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Fluoxetine.Experimental
BezitramideThe risk or severity of serotonin syndrome can be increased when Bezitramide is combined with Fluoxetine.Experimental, Illicit, Withdrawn
BicalutamideThe metabolism of Fluoxetine can be decreased when combined with Bicalutamide.Approved
BifemelaneThe risk or severity of adverse effects can be increased when Bifemelane is combined with Fluoxetine.Experimental
BifeprunoxThe risk or severity of adverse effects can be increased when Bifeprunox is combined with Fluoxetine.Investigational
BilastineThe risk or severity of QTc prolongation can be increased when Bilastine is combined with Fluoxetine.Approved, Investigational
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Fluoxetine.Approved, Investigational
BisoprololThe serum concentration of Bisoprolol can be increased when it is combined with Fluoxetine.Approved
BivalirudinFluoxetine may increase the antiplatelet activities of Bivalirudin.Approved, Investigational
BL-1020The risk or severity of adverse effects can be increased when BL-1020 is combined with Fluoxetine.Investigational
BlonanserinThe risk or severity of adverse effects can be increased when Blonanserin is combined with Fluoxetine.Approved, Investigational
BoceprevirThe metabolism of Fluoxetine can be decreased when combined with Boceprevir.Approved, Withdrawn
BopindololThe serum concentration of Bopindolol can be increased when it is combined with Fluoxetine.Approved
BornaprineThe risk or severity of adverse effects can be increased when Bornaprine is combined with Fluoxetine.Experimental
BortezomibThe risk or severity of QTc prolongation can be increased when Bortezomib is combined with Fluoxetine.Approved, Investigational
BosentanThe serum concentration of Fluoxetine can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Fluoxetine.Approved
Botulinum Toxin Type AThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Botulinum Toxin Type B.Approved, Investigational
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Fluoxetine.Approved, Investigational
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Fluoxetine.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.Approved
BrinaseFluoxetine may increase the antiplatelet activities of Brinase.Experimental
BrivaracetamThe risk or severity of adverse effects can be increased when Brivaracetam is combined with Fluoxetine.Approved, Investigational
BrofaromineThe risk or severity of adverse effects can be increased when Brofaromine is combined with Fluoxetine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Fluoxetine.Approved, Illicit, Investigational
BromfenacFluoxetine may increase the antiplatelet activities of Bromfenac.Approved
BromisovalThe risk or severity of adverse effects can be increased when Bromisoval is combined with Fluoxetine.Experimental
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Fluoxetine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Bromperidol is combined with Fluoxetine.Approved, Investigational
BrompheniramineThe risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Fluoxetine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Fluoxetine.Approved, Investigational, Withdrawn
BucindololThe serum concentration of Bucindolol can be increased when it is combined with Fluoxetine.Investigational
BuclizineThe risk or severity of QTc prolongation can be increased when Buclizine is combined with Fluoxetine.Approved
BufexamacFluoxetine may increase the antiplatelet activities of Bufexamac.Approved, Experimental
BuflomedilFluoxetine may increase the antiplatelet activities of Buflomedil.Experimental
BuforminFluoxetine may increase the hypoglycemic activities of Buformin.Investigational, Withdrawn
BufotenineThe risk or severity of adverse effects can be increased when Bufotenine is combined with Fluoxetine.Experimental, Illicit
BufuralolThe serum concentration of Bufuralol can be increased when it is combined with Fluoxetine.Experimental, Investigational
BupranololThe serum concentration of Bupranolol can be increased when it is combined with Fluoxetine.Approved
BuprenorphineFluoxetine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuserelinThe risk or severity of QTc prolongation can be increased when Buserelin is combined with Fluoxetine.Approved, Investigational
BuspironeBuspirone may increase the serotonergic activities of Fluoxetine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Fluoxetine.Approved, Illicit
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Fluoxetine.Approved, Illicit
ButaperazineThe risk or severity of adverse effects can be increased when Butaperazine is combined with Fluoxetine.Experimental
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Fluoxetine.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Fluoxetine.Approved, Illicit, Vet Approved
ButriptylineThe risk or severity of QTc prolongation can be increased when Butriptyline is combined with Fluoxetine.Approved
ButylphthalideFluoxetine may increase the antiplatelet activities of Butylphthalide.Investigational
ButylscopolamineThe risk or severity of adverse effects can be increased when Butylscopolamine is combined with Fluoxetine.Approved, Investigational, Vet Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Fluoxetine.Approved
CabergolineThe metabolism of Cabergoline can be decreased when combined with Fluoxetine.Approved
CaffeineThe metabolism of Fluoxetine can be decreased when combined with Caffeine.Approved
CamazepamThe risk or severity of adverse effects can be increased when Camazepam is combined with Fluoxetine.Approved, Illicit
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Fluoxetine.Experimental
CamylofinThe risk or severity of adverse effects can be increased when Camylofin is combined with Fluoxetine.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Fluoxetine.Approved
CangrelorFluoxetine may increase the antiplatelet activities of Cangrelor.Approved
CannabidivarinThe risk or severity of adverse effects can be increased when Cannabidivarin is combined with Fluoxetine.Investigational
CapreomycinThe risk or severity of adverse effects can be increased when Capreomycin is combined with Fluoxetine.Approved
CaptodiameThe risk or severity of adverse effects can be increased when Captodiame is combined with Fluoxetine.Approved, Investigational
CarbamazepineThe metabolism of Carbamazepine can be decreased when combined with Fluoxetine.Approved, Investigational
CarbinoxamineThe risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Fluoxetine.Approved
CarbromalThe risk or severity of adverse effects can be increased when Carbromal is combined with Fluoxetine.Experimental
CarbutamideFluoxetine may increase the hypoglycemic activities of Carbutamide.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Fluoxetine.Illicit, Investigational, Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Fluoxetine.Approved, Investigational
CariprazineThe risk or severity of adverse effects can be increased when Cariprazine is combined with Fluoxetine.Approved, Investigational
CarisbamateThe risk or severity of adverse effects can be increased when Carisbamate is combined with Fluoxetine.Investigational
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Fluoxetine.Approved
CarmegliptinFluoxetine may increase the hypoglycemic activities of Carmegliptin.Investigational
CaroxazoneCaroxazone may increase the serotonergic activities of Fluoxetine.Withdrawn
CarprofenFluoxetine may increase the antiplatelet activities of Carprofen.Approved, Vet Approved, Withdrawn
CarteololThe serum concentration of Carteolol can be increased when it is combined with Fluoxetine.Approved
CathinoneThe risk or severity of adverse effects can be increased when Cathinone is combined with Fluoxetine.Illicit
CelecoxibThe risk or severity of gastrointestinal bleeding and gastrointestinal ulceration can be increased when Fluoxetine is combined with Celecoxib.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Fluoxetine.Approved, Investigational
CeritinibThe serum concentration of Fluoxetine can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Fluoxetine.Approved, Withdrawn
Cerliponase alfaThe serum concentration of Cerliponase alfa can be increased when it is combined with Fluoxetine.Approved, Investigational
CertoparinFluoxetine may increase the antiplatelet activities of Certoparin.Approved, Investigational
CetirizineThe risk or severity of QTc prolongation can be increased when Cetirizine is combined with Fluoxetine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Fluoxetine.Approved, Illicit, Investigational, Vet Approved
ChlorambucilThe serum concentration of Chlorambucil can be increased when it is combined with Fluoxetine.Approved
ChlorcyclizineThe risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Fluoxetine.Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Fluoxetine.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Fluoxetine.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Fluoxetine.Approved
ChloroquineThe risk or severity of QTc prolongation can be increased when Chloroquine is combined with Fluoxetine.Approved, Investigational, Vet Approved
ChlorothiazideThe risk or severity of hyponatremia can be increased when Fluoxetine is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Fluoxetine.Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Chlorphenesin is combined with Fluoxetine.Approved, Vet Approved, Withdrawn
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Fluoxetine.Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Chlorproethazine is combined with Fluoxetine.Experimental
ChlorpromazineThe risk or severity of QTc prolongation can be increased when Chlorpromazine is combined with Fluoxetine.Approved, Investigational, Vet Approved
ChlorpropamideFluoxetine may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
ChlorprothixeneThe risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Fluoxetine.Approved, Investigational, Withdrawn
ChlortetracyclineThe risk or severity of adverse effects can be increased when Chlortetracycline is combined with Fluoxetine.Approved, Investigational, Vet Approved
ChlorthalidoneThe risk or severity of hyponatremia can be increased when Fluoxetine is combined with Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Fluoxetine.Approved
CholecalciferolThe metabolism of Fluoxetine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
Choline magnesium trisalicylateFluoxetine may increase the antiplatelet activities of Choline magnesium trisalicylate.Approved
CiglitazoneFluoxetine may increase the hypoglycemic activities of Ciglitazone.Experimental
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Fluoxetine.Approved, Investigational
CimetidineThe metabolism of Fluoxetine can be decreased when combined with Cimetidine.Approved, Investigational
CimicoxibThe risk or severity of gastrointestinal bleeding and gastrointestinal ulceration can be increased when Fluoxetine is combined with Cimicoxib.Investigational
CinacalcetThe metabolism of Fluoxetine can be decreased when combined with Cinacalcet.Approved
CinnarizineThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Fluoxetine.Approved, Investigational
CinolazepamThe risk or severity of adverse effects can be increased when Cinolazepam is combined with Fluoxetine.Approved
CinoxacinThe risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Fluoxetine.Approved, Investigational, Withdrawn
CiprofloxacinThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Fluoxetine.Approved, Investigational
CisaprideThe risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Cisapride.Approved, Investigational, Withdrawn
CisatracuriumThe risk or severity of adverse effects can be increased when Cisatracurium is combined with Fluoxetine.Approved
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Fluoxetine.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Fluoxetine.Approved
ClarithromycinThe risk or severity of QTc prolongation can be increased when Clarithromycin is combined with Fluoxetine.Approved
ClemastineThe risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Clemastine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Fluoxetine.Approved
ClindamycinThe risk or severity of adverse effects can be increased when Clindamycin is combined with Fluoxetine.Approved, Vet Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Fluoxetine.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Fluoxetine.Investigational
ClomipramineThe risk or severity of QTc prolongation can be increased when Clomipramine is combined with Fluoxetine.Approved, Investigational, Vet Approved
ClomocyclineThe risk or severity of adverse effects can be increased when Clomocycline is combined with Fluoxetine.Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Fluoxetine.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Fluoxetine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Clopenthixol is combined with Fluoxetine.Experimental
ClopidogrelThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Fluoxetine resulting in a loss in efficacy.Approved
CloranololThe serum concentration of Cloranolol can be increased when it is combined with Fluoxetine.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Fluoxetine.Approved, Illicit
CloricromenFluoxetine may increase the antiplatelet activities of Cloricromen.Experimental
ClorindioneFluoxetine may increase the antiplatelet activities of Clorindione.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Clothiapine is combined with Fluoxetine.Experimental
ClotiazepamThe risk or severity of adverse effects can be increased when Clotiazepam is combined with Fluoxetine.Approved, Illicit
ClotrimazoleThe metabolism of Fluoxetine can be decreased when combined with Clotrimazole.Approved, Vet Approved
CloxazolamThe risk or severity of adverse effects can be increased when Cloxazolam is combined with Fluoxetine.Approved, Investigational
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Fluoxetine.Approved
CobicistatThe serum concentration of Fluoxetine can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Fluoxetine.Approved, Investigational
CocaineThe risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Cocaine.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Fluoxetine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Fluoxetine.Approved
ColistimethateThe risk or severity of adverse effects can be increased when Colistimethate is combined with Fluoxetine.Approved, Vet Approved
ColistinThe risk or severity of adverse effects can be increased when Colistin is combined with Fluoxetine.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Fluoxetine.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be increased when it is combined with Fluoxetine.Approved
CopanlisibThe serum concentration of Copanlisib can be increased when it is combined with Fluoxetine.Approved, Investigational
CoumaphosThe therapeutic efficacy of Fluoxetine can be decreased when used in combination with Coumaphos.Vet Approved
CrizotinibThe risk or severity of QTc prolongation can be increased when Crizotinib is combined with Fluoxetine.Approved
CUDC-101The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Fluoxetine.Investigational
CUDC-907The risk or severity of QTc prolongation can be increased when CUDC-907 is combined with Fluoxetine.Investigational
CurcuminThe metabolism of Fluoxetine can be decreased when combined with Curcumin.Approved, Investigational
CyamemazineThe risk or severity of adverse effects can be increased when Cyamemazine is combined with Fluoxetine.Approved
CyclizineThe risk or severity of QTc prolongation can be increased when Cyclizine is combined with Fluoxetine.Approved
CyclobarbitalThe risk or severity of adverse effects can be increased when Cyclobarbital is combined with Fluoxetine.Experimental
CyclobenzaprineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Cyclobenzaprine.Approved
CyclopenthiazideThe risk or severity of hyponatremia can be increased when Fluoxetine is combined with Cyclopenthiazide.Experimental
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Fluoxetine.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Fluoxetine.Approved, Investigational
CyclopropaneThe risk or severity of adverse effects can be increased when Cyclopropane is combined with Fluoxetine.Experimental
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Fluoxetine.Approved, Investigational, Vet Approved
CycrimineThe risk or severity of adverse effects can be increased when Cycrimine is combined with Fluoxetine.Approved
CyproheptadineThe therapeutic efficacy of Fluoxetine can be decreased when used in combination with Cyproheptadine.Approved
Cyproterone acetateThe serum concentration of Fluoxetine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
CytarabineThe serum concentration of Cytarabine can be increased when it is combined with Fluoxetine.Approved, Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Fluoxetine.Approved
DabrafenibThe serum concentration of Fluoxetine can be decreased when it is combined with Dabrafenib.Approved, Investigational
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Fluoxetine.Approved, Investigational
DalteparinFluoxetine may increase the antiplatelet activities of Dalteparin.Approved
DanaparoidFluoxetine may increase the antiplatelet activities of Danaparoid.Approved, Withdrawn
DanazolThe metabolism of Fluoxetine can be decreased when combined with Danazol.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Fluoxetine.Approved, Investigational
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Fluoxetine.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Fluoxetine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Fluoxetine.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Fluoxetine.Approved, Investigational
DarexabanFluoxetine may increase the antiplatelet activities of Darexaban.Investigational
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Fluoxetine.Approved, Investigational
DarunavirThe serum concentration of Fluoxetine can be increased when it is combined with Darunavir.Approved
DasabuvirThe serum concentration of Dasabuvir can be increased when it is combined with Fluoxetine.Approved
DasatinibThe serum concentration of Fluoxetine can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Fluoxetine.Approved
DeanolThe risk or severity of adverse effects can be increased when Deanol is combined with Fluoxetine.Experimental
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Fluoxetine.Approved, Investigational
DecamethoniumThe therapeutic efficacy of Fluoxetine can be decreased when used in combination with Decamethonium.Approved
DeferasiroxThe serum concentration of Fluoxetine can be decreased when it is combined with Deferasirox.Approved, Investigational
DefibrotideFluoxetine may increase the antiplatelet activities of Defibrotide.Approved, Investigational
DegarelixThe risk or severity of QTc prolongation can be increased when Degarelix is combined with Fluoxetine.Approved
DelamanidThe risk or severity of QTc prolongation can be increased when Delamanid is combined with Fluoxetine.Approved, Investigational
DelavirdineThe metabolism of Fluoxetine can be decreased when combined with Delavirdine.Approved
DelorazepamThe risk or severity of adverse effects can be increased when Delorazepam is combined with Fluoxetine.Approved, Illicit, Investigational
DemecariumThe therapeutic efficacy of Fluoxetine can be decreased when used in combination with Demecarium.Approved
DemeclocyclineThe risk or severity of adverse effects can be increased when Demeclocycline is combined with Fluoxetine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Fluoxetine.Investigational
DesfluraneThe risk or severity of QTc prolongation can be increased when Desflurane is combined with Fluoxetine.Approved
DesipramineThe risk or severity of QTc prolongation can be increased when Desipramine is combined with Fluoxetine.Approved, Investigational
DesirudinFluoxetine may increase the antiplatelet activities of Desirudin.Approved
DesloratadineThe risk or severity of QTc prolongation can be increased when Desloratadine is combined with Fluoxetine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Desmopressin.Approved
DesmoteplaseFluoxetine may increase the antiplatelet activities of Desmoteplase.Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Fluoxetine.Vet Approved
DeutetrabenazineThe serum concentration of the active metabolites of Deutetrabenazine can be increased when Deutetrabenazine is used in combination with Fluoxetine.Approved, Investigational
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Fluoxetine.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Fluoxetine.Approved
DexchlorpheniramineThe risk or severity of QTc prolongation can be increased when Dexchlorpheniramine is combined with Fluoxetine.Experimental, Investigational
Dexchlorpheniramine maleateThe risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Fluoxetine.Approved
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Fluoxetine.Withdrawn
DexibuprofenFluoxetine may increase the antiplatelet activities of Dexibuprofen.Approved, Investigational
DexketoprofenFluoxetine may increase the antiplatelet activities of Dexketoprofen.Approved, Investigational
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Fluoxetine.Approved, Vet Approved
DexrabeprazoleThe metabolism of Dexrabeprazole can be decreased when combined with Fluoxetine.Experimental
DextofisopamThe risk or severity of adverse effects can be increased when Dextofisopam is combined with Fluoxetine.Investigational
DextranFluoxetine may increase the antiplatelet activities of Dextran.Approved, Investigational, Vet Approved
DextromethorphanFluoxetine may increase the serotonergic activities of Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Fluoxetine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Fluoxetine.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Fluoxetine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Fluoxetine.Approved, Illicit, Investigational, Vet Approved
DibekacinThe risk or severity of adverse effects can be increased when Dibekacin is combined with Fluoxetine.Experimental
DibenzepinThe risk or severity of adverse effects can be increased when Dibenzepin is combined with Fluoxetine.Experimental
DichloralphenazoneThe risk or severity of adverse effects can be increased when Dichloralphenazone is combined with Fluoxetine.Approved, Illicit
DichlorvosThe therapeutic efficacy of Fluoxetine can be decreased when used in combination with Dichlorvos.Vet Approved
DiclofenacFluoxetine may increase the antiplatelet activities of Diclofenac.Approved, Vet Approved
DicoumarolFluoxetine may increase the antiplatelet activities of Dicoumarol.Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Fluoxetine.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Diethyl ether is combined with Fluoxetine.Experimental
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Fluoxetine.Approved, Investigational
DifemerineThe risk or severity of adverse effects can be increased when Difemerine is combined with Fluoxetine.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Fluoxetine.Approved, Illicit
DifloxacinThe risk or severity of QTc prolongation can be increased when Difloxacin is combined with Fluoxetine.Vet Approved
DiflunisalFluoxetine may increase the antiplatelet activities of Diflunisal.Approved, Investigational
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Fluoxetine.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Fluoxetine.Approved
DihexyverineThe risk or severity of adverse effects can be increased when Dihexyverine is combined with Fluoxetine.Experimental
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Fluoxetine.Approved, Illicit
DihydroergocornineThe metabolism of Dihydroergocornine can be decreased when combined with Fluoxetine.Approved
DihydroergocristineThe metabolism of Dihydroergocristine can be decreased when combined with Fluoxetine.Approved, Experimental
DihydroergocryptineThe metabolism of Dihydroergocryptine can be decreased when combined with Fluoxetine.Experimental
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Fluoxetine.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Fluoxetine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Fluoxetine.Experimental, Illicit
DihydrostreptomycinThe risk or severity of adverse effects can be increased when Dihydrostreptomycin is combined with Fluoxetine.Investigational, Vet Approved
DiltiazemThe metabolism of Fluoxetine can be decreased when combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Fluoxetine.Approved
DimetacrineThe risk or severity of adverse effects can be increased when Dimetacrine is combined with Fluoxetine.Approved, Withdrawn
DimethyltryptamineThe risk or severity of adverse effects can be increased when Dimethyltryptamine is combined with Fluoxetine.Experimental, Illicit
DimetindeneThe risk or severity of adverse effects can be increased when Dimetindene is combined with Fluoxetine.Approved, Investigational
DiphemanilThe risk or severity of adverse effects can be increased when Diphemanil is combined with Fluoxetine.Experimental
Diphemanil MethylsulfateThe risk or severity of adverse effects can be increased when Diphemanil Methylsulfate is combined with Fluoxetine.Approved, Vet Approved, Withdrawn
DiphenadioneFluoxetine may increase the antiplatelet activities of Diphenadione.Experimental
DiphenhydramineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Fluoxetine.Approved, Investigational
DiphenidolThe risk or severity of adverse effects can be increased when Diphenidol is combined with Fluoxetine.Approved, Investigational, Withdrawn
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Fluoxetine.Approved, Illicit
DipyridamoleFluoxetine may increase the antiplatelet activities of Dipyridamole.Approved
DisopyramideThe risk or severity of QTc prolongation can be increased when Disopyramide is combined with Fluoxetine.Approved
DistigmineThe therapeutic efficacy of Fluoxetine can be decreased when used in combination with Distigmine.Experimental
DitazoleFluoxetine may increase the antiplatelet activities of Ditazole.Approved, Withdrawn
DixyrazineThe risk or severity of adverse effects can be increased when Dixyrazine is combined with Fluoxetine.Experimental
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Fluoxetine.Approved, Investigational
DofetilideThe risk or severity of QTc prolongation can be increased when Dofetilide is combined with Fluoxetine.Approved, Investigational
DolasetronThe risk or severity of QTc prolongation can be increased when Dolasetron is combined with Fluoxetine.Approved, Investigational
DolutegravirThe serum concentration of Dolutegravir can be increased when it is combined with Fluoxetine.Approved
Domoic AcidThe risk or severity of adverse effects can be increased when Domoic Acid is combined with Fluoxetine.Experimental
DomperidoneThe risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Domperidone.Approved, Investigational, Vet Approved
DonepezilThe therapeutic efficacy of Fluoxetine can be decreased when used in combination with Donepezil.Approved
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Fluoxetine.Vet Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Fluoxetine.Approved
DotarizineThe risk or severity of adverse effects can be increased when Dotarizine is combined with Fluoxetine.Investigational
DoxacuriumThe risk or severity of adverse effects can be increased when Doxacurium is combined with Fluoxetine.Approved
DoxefazepamThe risk or severity of adverse effects can be increased when Doxefazepam is combined with Fluoxetine.Experimental
DoxepinThe risk or severity of QTc prolongation can be increased when Doxepin is combined with Fluoxetine.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Fluoxetine.Approved, Investigational
DoxycyclineThe risk or severity of adverse effects can be increased when Doxycycline is combined with Fluoxetine.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Fluoxetine.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.Approved, Illicit
DronedaroneThe risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Fluoxetine.Experimental, Illicit
Drotrecogin alfaFluoxetine may increase the antiplatelet activities of Drotrecogin alfa.Approved, Investigational, Withdrawn
DroxicamFluoxetine may increase the antiplatelet activities of Droxicam.Withdrawn
DulaglutideFluoxetine may increase the hypoglycemic activities of Dulaglutide.Approved, Investigational
DuloxetineThe serum concentration of Duloxetine can be increased when it is combined with Fluoxetine.Approved
DutogliptinFluoxetine may increase the hypoglycemic activities of Dutogliptin.Investigational
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Fluoxetine.Approved
EbastineThe risk or severity of QTc prolongation can be increased when Ebastine is combined with Fluoxetine.Approved, Investigational
EchothiophateThe therapeutic efficacy of Fluoxetine can be decreased when used in combination with Echothiophate.Approved
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Fluoxetine.Investigational
Edetic AcidFluoxetine may increase the antiplatelet activities of Edetic Acid.Approved, Vet Approved
EdivoxetineThe risk or severity of adverse effects can be increased when Edivoxetine is combined with Fluoxetine.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Fluoxetine.Approved
EdrophoniumThe therapeutic efficacy of Fluoxetine can be decreased when used in combination with Edrophonium.Approved
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Fluoxetine.Approved, Investigational
ElagolixThe metabolism of Elagolix can be decreased when combined with Fluoxetine.Approved, Investigational
ElbasvirThe serum concentration of Elbasvir can be increased when it is combined with Fluoxetine.Approved
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Fluoxetine.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Fluoxetine.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with Fluoxetine.Investigational
EluxadolineThe risk or severity of serotonin syndrome can be increased when Eluxadoline is combined with Fluoxetine.Approved, Investigational
EmedastineThe risk or severity of QTc prolongation can be increased when Emedastine is combined with Fluoxetine.Approved
EmeproniumThe risk or severity of adverse effects can be increased when Emepronium is combined with Fluoxetine.Experimental
EmpagliflozinFluoxetine may increase the hypoglycemic activities of Empagliflozin.Approved
EmylcamateThe risk or severity of adverse effects can be increased when Emylcamate is combined with Fluoxetine.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Fluoxetine.Approved, Investigational, Vet Approved
EnglitazoneFluoxetine may increase the hypoglycemic activities of Englitazone.Experimental
EnoxacinThe risk or severity of QTc prolongation can be increased when Enoxacin is combined with Fluoxetine.Approved, Investigational
EnoxaparinFluoxetine may increase the antiplatelet activities of Enoxaparin.Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Fluoxetine.Approved, Investigational
EntinostatThe risk or severity of QTc prolongation can be increased when Entinostat is combined with Fluoxetine.Investigational
EnzalutamideThe serum concentration of Fluoxetine can be decreased when it is combined with Enzalutamide.Approved
EpanololThe serum concentration of Epanolol can be increased when it is combined with Fluoxetine.Experimental
EperisoneThe risk or severity of adverse effects can be increased when Eperisone is combined with Fluoxetine.Approved, Investigational
EpinastineThe risk or severity of QTc prolongation can be increased when Epinastine is combined with Fluoxetine.Approved, Investigational
EpitizideThe risk or severity of hyponatremia can be increased when Fluoxetine is combined with Epitizide.Experimental
EpoprostenolFluoxetine may increase the antiplatelet activities of Epoprostenol.Approved
EptifibatideFluoxetine may increase the antiplatelet activities of Eptifibatide.Approved, Investigational
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Fluoxetine.Approved
ErgonovineThe metabolism of Ergonovine can be decreased when combined with Fluoxetine.Approved
ErgotamineThe metabolism of Ergotamine can be decreased when combined with Fluoxetine.Approved
EribulinThe risk or severity of QTc prolongation can be increased when Eribulin is combined with Fluoxetine.Approved, Investigational
ErlotinibThe risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Erlotinib.Approved, Investigational
ErtugliflozinThe serum concentration of Ertugliflozin can be increased when it is combined with Fluoxetine.Approved, Investigational
ErythromycinThe risk or severity of QTc prolongation can be increased when Erythromycin is combined with Fluoxetine.Approved, Investigational, Vet Approved
EsatenololThe serum concentration of Esatenolol can be increased when it is combined with Fluoxetine.Experimental
EscitalopramThe risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Escitalopram.Approved, Investigational
EslicarbazepineThe risk or severity of adverse effects can be increased when Eslicarbazepine is combined with Fluoxetine.Approved
Eslicarbazepine acetateThe risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Fluoxetine.Approved
EsmirtazapineThe risk or severity of adverse effects can be increased when Esmirtazapine is combined with Fluoxetine.Investigational
EsmololThe serum concentration of Esmolol can be increased when it is combined with Fluoxetine.Approved
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Fluoxetine.Approved, Investigational
EsreboxetineThe risk or severity of adverse effects can be increased when Esreboxetine is combined with Fluoxetine.Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Fluoxetine.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Fluoxetine.Approved, Investigational, Vet Approved
Estradiol acetateThe serum concentration of Estradiol acetate can be increased when it is combined with Fluoxetine.Approved, Investigational, Vet Approved
Estradiol benzoateThe serum concentration of Estradiol benzoate can be increased when it is combined with Fluoxetine.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Estradiol cypionate can be increased when it is combined with Fluoxetine.Approved, Investigational, Vet Approved
Estradiol dienanthateThe serum concentration of Estradiol dienanthate can be increased when it is combined with Fluoxetine.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Estradiol valerate can be increased when it is combined with Fluoxetine.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Fluoxetine.Approved, Investigational, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Fluoxetine.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Fluoxetine.Approved, Investigational
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Fluoxetine.Approved, Investigational
EtanautineThe risk or severity of adverse effects can be increased when Etanautine is combined with Fluoxetine.Experimental
EthadioneThe risk or severity of adverse effects can be increased when Ethadione is combined with Fluoxetine.Experimental
EthanolFluoxetine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fluoxetine.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Fluoxetine.Approved
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Fluoxetine.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Fluoxetine.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Fluoxetine.Approved
Ethyl biscoumacetateFluoxetine may increase the antiplatelet activities of Ethyl biscoumacetate.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Fluoxetine.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl chloride is combined with Fluoxetine.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Fluoxetine.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Fluoxetine.Approved, Illicit
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Fluoxetine.Investigational, Withdrawn
EtiracetamThe risk or severity of adverse effects can be increased when Etiracetam is combined with Fluoxetine.Investigational
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Fluoxetine.Approved
EtodolacFluoxetine may increase the antiplatelet activities of Etodolac.Approved, Investigational, Vet Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Fluoxetine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Etoperidone is combined with Fluoxetine.Withdrawn
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Fluoxetine.Approved
EtoricoxibThe risk or severity of gastrointestinal bleeding and gastrointestinal ulceration can be increased when Fluoxetine is combined with Etoricoxib.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Fluoxetine.Illicit, Vet Approved
EtravirineThe metabolism of Etravirine can be decreased when combined with Fluoxetine.Approved
EtybenzatropineThe risk or severity of adverse effects can be increased when Etybenzatropine is combined with Fluoxetine.Experimental
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Fluoxetine.Approved
EvogliptinFluoxetine may increase the hypoglycemic activities of Evogliptin.Investigational
ExenatideFluoxetine may increase the hypoglycemic activities of Exenatide.Approved, Investigational
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Fluoxetine.Approved
EzogabineThe risk or severity of QTc prolongation can be increased when Ezogabine is combined with Fluoxetine.Approved, Investigational
FabomotizoleThe risk or severity of adverse effects can be increased when Fabomotizole is combined with Fluoxetine.Experimental
FamotidineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Fluoxetine.Approved
Fazadinium bromideThe risk or severity of adverse effects can be increased when Fazadinium bromide is combined with Fluoxetine.Experimental
FebarbamateThe risk or severity of adverse effects can be increased when Febarbamate is combined with Fluoxetine.Experimental
FelbamateThe risk or severity of QTc prolongation can be increased when Felbamate is combined with Fluoxetine.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Fluoxetine.Approved, Illicit, Withdrawn
FenoprofenFluoxetine may increase the antiplatelet activities of Fenoprofen.Approved
FenpiveriniumThe risk or severity of adverse effects can be increased when Fenpiverinium is combined with Fluoxetine.Experimental
FentanylThe risk or severity of serotonin syndrome can be increased when Fluoxetine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Fluoxetine can be decreased when used in combination with Fenthion.Vet Approved
FenyramidolThe risk or severity of adverse effects can be increased when Fenyramidol is combined with Fluoxetine.Experimental
Ferulic acidFluoxetine may increase the antiplatelet activities of Ferulic acid.Experimental
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Fluoxetine.Approved
FexofenadineThe risk or severity of QTc prolongation can be increased when Fexofenadine is combined with Fluoxetine.Approved, Investigational
FibrinolysinFluoxetine may increase the antiplatelet activities of Fibrinolysin.Investigational
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Fluoxetine.Approved
FingolimodThe risk or severity of QTc prolongation can be increased when Fingolimod is combined with Fluoxetine.Approved, Investigational
FirocoxibThe risk or severity of gastrointestinal bleeding and gastrointestinal ulceration can be increased when Fluoxetine is combined with Firocoxib.Experimental, Vet Approved
FlavoxateThe risk or severity of adverse effects can be increased when Flavoxate is combined with Fluoxetine.Approved
FlecainideThe risk or severity of QTc prolongation can be increased when Flecainide is combined with Fluoxetine.Approved, Withdrawn
FleroxacinThe risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Fluoxetine.Approved
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Fluoxetine.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Fluanisone is combined with Fluoxetine.Experimental
Fluciclovine (18F)The serum concentration of Fluciclovine (18F) can be increased when it is combined with Fluoxetine.Approved
FluconazoleThe risk or severity of QTc prolongation can be increased when Fluconazole is combined with Fluoxetine.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Fluoxetine.Approved, Illicit
FluindioneFluoxetine may increase the antiplatelet activities of Fluindione.Approved, Investigational
FlumequineThe risk or severity of QTc prolongation can be increased when Flumequine is combined with Fluoxetine.Withdrawn
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Fluoxetine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Fluoxetine.Approved, Illicit
FlupentixolThe risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Flupentixol.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Fluoxetine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Fluoxetine.Approved, Illicit, Investigational
FlurbiprofenFluoxetine may increase the antiplatelet activities of Flurbiprofen.Approved, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Fluspirilene.Approved, Investigational
FluticasoneThe serum concentration of Fluticasone can be increased when it is combined with Fluoxetine.Approved, Experimental, Investigational
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Fluoxetine.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Fluoxetine.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Fluoxetine.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Fluvoxamine.Approved, Investigational
FondaparinuxFluoxetine may increase the antiplatelet activities of Fondaparinux.Approved, Investigational
FormoterolThe risk or severity of QTc prolongation can be increased when Formoterol is combined with Fluoxetine.Approved, Investigational
FosamprenavirThe metabolism of Fluoxetine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Fluoxetine can be increased when it is combined with Fosaprepitant.Approved
FoscarnetThe risk or severity of QTc prolongation can be increased when Foscarnet is combined with Fluoxetine.Approved
FosphenytoinThe risk or severity of Anticonvulsant Toxicity can be increased when Fluoxetine is combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Fluoxetine.Approved, Illicit, Investigational
FramycetinThe risk or severity of adverse effects can be increased when Framycetin is combined with Fluoxetine.Approved
FrovatriptanThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Frovatriptan.Approved, Investigational
FurazolidoneFurazolidone may increase the serotonergic activities of Fluoxetine.Approved, Investigational, Vet Approved
Fusidic AcidThe serum concentration of Fluoxetine can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Fluoxetine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Fluoxetine.Approved, Investigational
GabexateFluoxetine may increase the antiplatelet activities of Gabexate.Investigational
GaboxadolThe risk or severity of adverse effects can be increased when Gaboxadol is combined with Fluoxetine.Investigational
Gadobenic acidThe risk or severity of QTc prolongation can be increased when Gadobenic acid is combined with Fluoxetine.Approved, Investigational
GalantamineThe metabolism of Galantamine can be decreased when combined with Fluoxetine.Approved
GallamineThe risk or severity of adverse effects can be increased when Gallamine is combined with Fluoxetine.Experimental
Gallamine TriethiodideThe therapeutic efficacy of Fluoxetine can be decreased when used in combination with Gallamine Triethiodide.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Fluoxetine.Approved, Illicit, Investigational
Gantacurium ChlorideThe risk or severity of adverse effects can be increased when Gantacurium Chloride is combined with Fluoxetine.Investigational
GarenoxacinThe risk or severity of QTc prolongation can be increased when Garenoxacin is combined with Fluoxetine.Investigational
GatifloxacinThe risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Fluoxetine.Approved, Investigational
GedocarnilThe risk or severity of adverse effects can be increased when Gedocarnil is combined with Fluoxetine.Experimental
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Fluoxetine.Approved, Investigational
GemifloxacinThe risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Fluoxetine.Approved, Investigational
GemigliptinFluoxetine may increase the hypoglycemic activities of Gemigliptin.Investigational
GeneticinThe risk or severity of adverse effects can be increased when Geneticin is combined with Fluoxetine.Experimental
GentamicinThe risk or severity of adverse effects can be increased when Gentamicin is combined with Fluoxetine.Approved, Vet Approved
GENTAMICIN C1AThe risk or severity of adverse effects can be increased when GENTAMICIN C1A is combined with Fluoxetine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Fluoxetine.Investigational
Ginkgo bilobaThe therapeutic efficacy of Fluoxetine can be decreased when used in combination with Ginkgo biloba.Approved, Investigational, Nutraceutical
GivinostatThe risk or severity of QTc prolongation can be increased when Givinostat is combined with Fluoxetine.Investigational
GlecaprevirThe serum concentration of Glecaprevir can be increased when it is combined with Fluoxetine.Approved, Investigational
GlibornurideFluoxetine may increase the hypoglycemic activities of Glibornuride.Investigational, Withdrawn
GliclazideFluoxetine may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideFluoxetine may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideFluoxetine may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GliquidoneFluoxetine may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
GlisoxepideFluoxetine may increase the hypoglycemic activities of Glisoxepide.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Fluoxetine.Approved, Illicit
GlyburideFluoxetine may increase the hypoglycemic activities of Glyburide.Approved
Glycerol PhenylbutyrateThe metabolism of Fluoxetine can be decreased when combined with Glycerol Phenylbutyrate.Approved
GlycodiazineFluoxetine may increase the hypoglycemic activities of Glycodiazine.Approved, Investigational
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Fluoxetine.Approved, Investigational, Vet Approved
GoserelinThe risk or severity of QTc prolongation can be increased when Goserelin is combined with Fluoxetine.Approved
GosogliptinFluoxetine may increase the hypoglycemic activities of Gosogliptin.Investigational
Gramicidin DThe serum concentration of Gramicidin D can be increased when it is combined with Fluoxetine.Approved
GranisetronThe risk or severity of QTc prolongation can be increased when Granisetron is combined with Fluoxetine.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Fluoxetine.Approved
GrepafloxacinThe risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Grepafloxacin.Approved, Investigational, Withdrawn
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Fluoxetine.Approved, Investigational
Guar gumFluoxetine may increase the hypoglycemic activities of Guar gum.Experimental
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Fluoxetine.Approved, Illicit, Withdrawn
HalofantrineThe risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Halofantrine.Approved
HaloperidolThe risk or severity of QTc prolongation and torsade de pointes can be increased when Fluoxetine is combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Fluoxetine.Approved, Vet Approved
HarmalineHarmaline may increase the serotonergic activities of Fluoxetine.Experimental
HeparinFluoxetine may increase the antiplatelet activities of Heparin.Approved, Investigational
HeptabarbitalThe risk or severity of adverse effects can be increased when Heptabarbital is combined with Fluoxetine.Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Fluoxetine.Approved, Illicit, Investigational
HexafluroniumThe risk or severity of adverse effects can be increased when Hexafluronium is combined with Fluoxetine.Approved
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Fluoxetine.Experimental
HexapropymateThe risk or severity of adverse effects can be increased when Hexapropymate is combined with Fluoxetine.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Fluoxetine.Approved
HexocycliumThe risk or severity of adverse effects can be increased when Hexocyclium is combined with Fluoxetine.Approved
HistrelinThe risk or severity of QTc prolongation can be increased when Histrelin is combined with Fluoxetine.Approved
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Fluoxetine.Approved
Homatropine MethylbromideThe risk or severity of adverse effects can be increased when Homatropine Methylbromide is combined with Fluoxetine.Approved
Huperzine AThe therapeutic efficacy of Fluoxetine can be decreased when used in combination with Huperzine A.Approved, Investigational
HydracarbazineHydracarbazine may increase the serotonergic activities of Fluoxetine.Experimental
HydrochlorothiazideThe risk or severity of hyponatremia can be increased when Fluoxetine is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe metabolism of Hydrocodone can be decreased when combined with Fluoxetine.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Fluoxetine.Approved, Vet Approved
HydroflumethiazideThe risk or severity of hyponatremia can be increased when Fluoxetine is combined with Hydroflumethiazide.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Fluoxetine.Approved, Illicit
HydroxychloroquineThe risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Fluoxetine.Approved
HydroxytyrosolFluoxetine may increase the antiplatelet activities of Hydroxytyrosol.Investigational
HydroxyureaThe serum concentration of Hydroxyurea can be increased when it is combined with Fluoxetine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.Approved
Hygromycin BThe risk or severity of adverse effects can be increased when Hygromycin B is combined with Fluoxetine.Vet Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Fluoxetine.Approved
HypericinThe risk or severity of adverse effects can be increased when Hypericin is combined with Fluoxetine.Investigational
IbandronateThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Fluoxetine.Approved, Investigational
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Fluoxetine.Approved
IbudilastFluoxetine may increase the antiplatelet activities of Ibudilast.Approved, Investigational
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Fluoxetine.Approved
IbutilideThe risk or severity of QTc prolongation can be increased when Ibutilide is combined with Fluoxetine.Approved
IcosapentFluoxetine may increase the antiplatelet activities of Icosapent.Approved, Nutraceutical
Icosapent ethylFluoxetine may increase the antiplatelet activities of Icosapent ethyl.Approved, Investigational, Nutraceutical
IdelalisibThe metabolism of Fluoxetine can be decreased when combined with Idelalisib.Approved
IdraparinuxFluoxetine may increase the antiplatelet activities of Idraparinux.Investigational
IfenprodilThe risk or severity of adverse effects can be increased when Ifenprodil is combined with Fluoxetine.Approved, Investigational, Withdrawn
IfetrobanFluoxetine may increase the antiplatelet activities of Ifetroban.Investigational
IloperidoneThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Fluoxetine.Approved
IloprostFluoxetine may increase the antiplatelet activities of Iloprost.Approved, Investigational
ImagabalinThe risk or severity of adverse effects can be increased when Imagabalin is combined with Fluoxetine.Investigational
ImatinibThe risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Imatinib.Approved
ImidafenacinThe risk or severity of adverse effects can be increased when Imidafenacin is combined with Fluoxetine.Approved, Investigational
ImipramineThe risk or severity of QTc prolongation can be increased when Imipramine is combined with Fluoxetine.Approved
Imipramine oxideThe risk or severity of adverse effects can be increased when Imipramine oxide is combined with Fluoxetine.Experimental
IndacaterolThe risk or severity of QTc prolongation can be increased when Indacaterol is combined with Fluoxetine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of QTc prolongation can be increased when Indapamide is combined with Fluoxetine.Approved
IndenololThe serum concentration of Indenolol can be increased when it is combined with Fluoxetine.Withdrawn
IndinavirThe metabolism of Fluoxetine can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with Fluoxetine.Investigational
IndobufenFluoxetine may increase the antiplatelet activities of Indobufen.Investigational
IndomethacinFluoxetine may increase the antiplatelet activities of Indomethacin.Approved, Investigational
Inotuzumab ozogamicinThe serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Fluoxetine.Approved, Investigational
Insulin AspartFluoxetine may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin BeefFluoxetine may increase the hypoglycemic activities of Insulin Beef.Approved
Insulin DegludecFluoxetine may increase the hypoglycemic activities of Insulin Degludec.Approved
Insulin DetemirFluoxetine may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineFluoxetine may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineFluoxetine may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanFluoxetine may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproFluoxetine may increase the hypoglycemic activities of Insulin Lispro.Approved
Insulin peglisproFluoxetine may increase the hypoglycemic activities of Insulin peglispro.Investigational
Insulin PorkFluoxetine may increase the hypoglycemic activities of Insulin Pork.Approved
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Fluoxetine.Approved, Investigational
Ioflupane I-123Fluoxetine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
IpidacrineThe therapeutic efficacy of Fluoxetine can be decreased when used in combination with Ipidacrine.Experimental
IpratropiumThe risk or severity of adverse effects can be increased when Ipratropium is combined with Fluoxetine.Approved
IprindoleThe risk or severity of adverse effects can be increased when Iprindole is combined with Fluoxetine.Experimental
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Fluoxetine.Withdrawn
IproniazidIproniazid may increase the serotonergic activities of Fluoxetine.Withdrawn
IrbesartanThe metabolism of Irbesartan can be decreased when combined with Fluoxetine.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Fluoxetine.Approved, Investigational
IsavuconazoleThe serum concentration of Fluoxetine can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Fluoxetine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsepamicinThe risk or severity of adverse effects can be increased when Isepamicin is combined with Fluoxetine.Experimental
IsocarboxazidThe therapeutic efficacy of Fluoxetine can be increased when used in combination with Isocarboxazid.Approved
IsofluraneThe risk or severity of QTc prolongation can be increased when Isoflurane is combined with Fluoxetine.Approved, Vet Approved
IsoflurophateThe therapeutic efficacy of Fluoxetine can be decreased when used in combination with Isoflurophate.Approved, Investigational, Withdrawn
IsoniazidThe metabolism of Fluoxetine can be decreased when combined with Isoniazid.Approved, Investigational
IsopropamideThe risk or severity of adverse effects can be increased when Isopropamide is combined with Fluoxetine.Approved, Vet Approved
IsradipineThe risk or severity of QTc prolongation can be increased when Isradipine is combined with Fluoxetine.Approved, Investigational
ItoprideThe therapeutic efficacy of Fluoxetine can be decreased when used in combination with Itopride.Investigational
ItraconazoleThe risk or severity of QTc prolongation can be increased when Itraconazole is combined with Fluoxetine.Approved, Investigational
IvabradineThe risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Ivabradine.Approved
IvacaftorThe serum concentration of Fluoxetine can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Fluoxetine.Approved, Investigational, Vet Approved
IvosidenibThe risk or severity of QTc prolongation can be increased when Ivosidenib is combined with Fluoxetine.Approved, Investigational
KanamycinThe risk or severity of adverse effects can be increased when Kanamycin is combined with Fluoxetine.Approved, Investigational, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Fluoxetine.Approved, Vet Approved
KetanserinFluoxetine may increase the antiplatelet activities of Ketanserin.Investigational
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Fluoxetine.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Fluoxetine.Approved, Investigational
KetoconazoleThe risk or severity of QTc prolongation can be increased when Ketoconazole is combined with Fluoxetine.Approved, Investigational
KetoprofenFluoxetine may increase the antiplatelet activities of Ketoprofen.Approved, Vet Approved
KetorolacFluoxetine may increase the antiplatelet activities of Ketorolac.Approved
KetotifenThe risk or severity of QTc prolongation can be increased when Ketotifen is combined with Fluoxetine.Approved
KRP-104Fluoxetine may increase the hypoglycemic activities of KRP-104.Investigational
L-TryptophanL-Tryptophan may increase the serotonergic activities of Fluoxetine.Approved, Nutraceutical, Withdrawn
LabetalolThe serum concentration of Labetalol can be increased when it is combined with Fluoxetine.Approved
LacosamideThe risk or severity of adverse effects can be increased when Lacosamide is combined with Fluoxetine.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Fluoxetine.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Fluoxetine.Approved, Investigational
LandiololThe serum concentration of Landiolol can be increased when it is combined with Fluoxetine.Investigational
LanicemineThe risk or severity of adverse effects can be increased when Lanicemine is combined with Fluoxetine.Investigational
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Fluoxetine.Approved, Investigational
LapatinibThe risk or severity of QTc prolongation can be increased when Lapatinib is combined with Fluoxetine.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Fluoxetine.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Fluoxetine.Approved
LenvatinibThe risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Fluoxetine.Approved, Investigational
LepirudinFluoxetine may increase the antiplatelet activities of Lepirudin.Approved
LetaxabanFluoxetine may increase the antiplatelet activities of Letaxaban.Investigational
LetermovirThe serum concentration of Letermovir can be increased when it is combined with Fluoxetine.Approved, Investigational
LeuprolideThe risk or severity of QTc prolongation can be increased when Leuprolide is combined with Fluoxetine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Fluoxetine.Approved, Investigational
LevobetaxololThe serum concentration of Levobetaxolol can be increased when it is combined with Fluoxetine.Approved, Investigational
LevobunololThe serum concentration of Levobunolol can be increased when it is combined with Fluoxetine.Approved
LevocabastineThe risk or severity of QTc prolongation can be increased when Levocabastine is combined with Fluoxetine.Approved, Investigational
LevocetirizineThe risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Fluoxetine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Fluoxetine.Approved
LevofloxacinThe risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Fluoxetine.Approved, Investigational
Levomethadyl AcetateThe risk or severity of QTc prolongation can be increased when Levomethadyl Acetate is combined with Fluoxetine.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Fluoxetine.Approved
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Fluoxetine.Approved
LidocaineThe metabolism of Fluoxetine can be decreased when combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Fluoxetine.Approved
LincomycinThe risk or severity of adverse effects can be increased when Lincomycin is combined with Fluoxetine.Approved, Vet Approved
LinezolidLinezolid may increase the serotonergic activities of Fluoxetine.Approved, Investigational
LinsidomineFluoxetine may increase the antiplatelet activities of Linsidomine.Experimental
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Fluoxetine.Approved, Vet Approved
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Fluoxetine.Approved
LiraglutideFluoxetine may increase the hypoglycemic activities of Liraglutide.Approved
LisurideThe metabolism of Lisuride can be decreased when combined with Fluoxetine.Approved, Investigational
Lithium carbonateThe risk or severity of adverse effects can be increased when Lithium carbonate is combined with Fluoxetine.Approved
Lithium cationLithium cation may increase the serotonergic activities of Fluoxetine.Experimental
LixisenatideFluoxetine may increase the hypoglycemic activities of Lixisenatide.Approved
LobeglitazoneFluoxetine may increase the hypoglycemic activities of Lobeglitazone.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Fluoxetine.Illicit
LofepramineThe risk or severity of adverse effects can be increased when Lofepramine is combined with Fluoxetine.Experimental
LofexidineThe therapeutic efficacy of Fluoxetine can be increased when used in combination with Lofexidine.Approved, Investigational
LomefloxacinThe risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Fluoxetine.Approved, Investigational
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Fluoxetine.Approved
LopinavirThe risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Loprazolam is combined with Fluoxetine.Experimental
LoratadineThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Fluoxetine.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Fluoxetine.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Fluoxetine.Approved
LornoxicamFluoxetine may increase the antiplatelet activities of Lornoxicam.Approved, Investigational
LorpiprazoleThe serum concentration of Fluoxetine can be increased when it is combined with Lorpiprazole.Approved
LortalamineThe risk or severity of adverse effects can be increased when Lortalamine is combined with Fluoxetine.Experimental
LosartanThe serum concentration of Losartan can be increased when it is combined with Fluoxetine.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Fluoxetine.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Fluoxetine.Approved
LuliconazoleThe serum concentration of Fluoxetine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Fluoxetine can be increased when combined with Lumacaftor.Approved
LumateperoneThe risk or severity of adverse effects can be increased when Lumateperone is combined with Fluoxetine.Investigational
LumefantrineThe risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Lumefantrine.Approved
LumiracoxibThe risk or severity of gastrointestinal bleeding and gastrointestinal ulceration can be increased when Fluoxetine is combined with Lumiracoxib.Approved, Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Fluoxetine.Approved, Investigational
LymecyclineThe risk or severity of adverse effects can be increased when Lymecycline is combined with Fluoxetine.Approved, Investigational
LynestrenolThe metabolism of Lynestrenol can be decreased when combined with Fluoxetine.Approved, Investigational
Lysergic Acid DiethylamideThe metabolism of Lysergic Acid Diethylamide can be decreased when combined with Fluoxetine.Illicit, Investigational, Withdrawn
MacimorelinThe risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Macimorelin.Approved, Investigational
Magnesium acetateThe risk or severity of adverse effects can be increased when Magnesium acetate is combined with Fluoxetine.Approved
Magnesium acetate tetrahydrateThe risk or severity of adverse effects can be increased when Magnesium acetate tetrahydrate is combined with Fluoxetine.Approved
Magnesium Aluminum SilicateThe risk or severity of adverse effects can be increased when Magnesium Aluminum Silicate is combined with Fluoxetine.Approved
Magnesium aspartateThe risk or severity of adverse effects can be increased when Magnesium aspartate is combined with Fluoxetine.Experimental
Magnesium carbonateThe risk or severity of adverse effects can be increased when Magnesium carbonate is combined with Fluoxetine.Approved, Investigational
Magnesium cationThe risk or severity of adverse effects can be increased when Magnesium cation is combined with Fluoxetine.Approved, Nutraceutical
Magnesium chlorideThe risk or severity of adverse effects can be increased when Magnesium chloride is combined with Fluoxetine.Approved
Magnesium citrateThe risk or severity of adverse effects can be increased when Magnesium citrate is combined with Fluoxetine.Approved
Magnesium gluconateThe risk or severity of adverse effects can be increased when Magnesium gluconate is combined with Fluoxetine.Approved, Investigational
Magnesium glycinateThe risk or severity of adverse effects can be increased when Magnesium glycinate is combined with Fluoxetine.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Magnesium hydroxide is combined with Fluoxetine.Approved, Investigational
Magnesium orotateThe risk or severity of adverse effects can be increased when Magnesium orotate is combined with Fluoxetine.Experimental
Magnesium oxideThe risk or severity of adverse effects can be increased when Magnesium oxide is combined with Fluoxetine.Approved
Magnesium phosphateThe risk or severity of adverse effects can be increased when Magnesium phosphate is combined with Fluoxetine.Experimental
Magnesium salicylateFluoxetine may increase the antiplatelet activities of Magnesium salicylate.Approved
Magnesium silicateThe risk or severity of adverse effects can be increased when Magnesium silicate is combined with Fluoxetine.Approved
Magnesium stearateThe risk or severity of adverse effects can be increased when Magnesium stearate is combined with Fluoxetine.Investigational
Magnesium sulfateThe therapeutic efficacy of Fluoxetine can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Fluoxetine.Approved
MalathionThe therapeutic efficacy of Fluoxetine can be decreased when used in combination with Malathion.Approved, Investigational
ManidipineThe metabolism of Fluoxetine can be decreased when combined with Manidipine.Approved, Investigational
MaprotilineThe risk or severity of QTc prolongation can be increased when Maprotiline is combined with Fluoxetine.Approved, Investigational
MazaticolThe risk or severity of adverse effects can be increased when Mazaticol is combined with Fluoxetine.Experimental
MazindolThe risk or severity of adverse effects can be increased when Mazindol is combined with Fluoxetine.Approved, Investigational
MebanazineMebanazine may increase the serotonergic activities of Fluoxetine.Withdrawn
MebeverineThe risk or severity of adverse effects can be increased when Mebeverine is combined with Fluoxetine.Approved, Investigational
MebicarThe risk or severity of adverse effects can be increased when Mebicar is combined with Fluoxetine.Experimental
MebutamateThe risk or severity of adverse effects can be increased when Mebutamate is combined with Fluoxetine.Approved
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Fluoxetine.Approved, Investigational
MecaserminFluoxetine may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Fluoxetine.Approved
Meclofenamic acidFluoxetine may increase the antiplatelet activities of Meclofenamic acid.Approved, Vet Approved
MedazepamThe risk or severity of adverse effects can be increased when Medazepam is combined with Fluoxetine.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Fluoxetine.Vet Approved
MedifoxamineThe risk or severity of adverse effects can be increased when Medifoxamine is combined with Fluoxetine.Experimental
Mefenamic acidFluoxetine may increase the antiplatelet activities of Mefenamic acid.Approved
MefloquineThe therapeutic efficacy of Fluoxetine can be decreased when used in combination with Mefloquine.Approved, Investigational
MelagatranFluoxetine may increase the antiplatelet activities of Melagatran.Experimental
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Fluoxetine.Approved, Nutraceutical, Vet Approved
MelitracenThe risk or severity of adverse effects can be increased when Melitracen is combined with Fluoxetine.Experimental, Investigational
MeloxicamFluoxetine may increase the antiplatelet activities of Meloxicam.Approved, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Fluoxetine.Approved, Investigational
MelphalanThe serum concentration of Melphalan can be increased when it is combined with Fluoxetine.Approved
MepenzolateThe risk or severity of adverse effects can be increased when Mepenzolate is combined with Fluoxetine.Approved
MephenesinThe risk or severity of adverse effects can be increased when Mephenesin is combined with Fluoxetine.Approved
MephenoxaloneThe risk or severity of adverse effects can be increased when Mephenoxalone is combined with Fluoxetine.Experimental
MephenytoinThe risk or severity of adverse effects can be increased when Mephenytoin is combined with Fluoxetine.Investigational, Withdrawn
MepindololThe serum concentration of Mepindolol can be increased when it is combined with Fluoxetine.Experimental
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Fluoxetine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Fluoxetine.Experimental
MepyramineThe risk or severity of QTc prolongation can be increased when Mepyramine is combined with Fluoxetine.Approved, Vet Approved
MequitazineThe serum concentration of Mequitazine can be increased when it is combined with Fluoxetine.Approved
MesalazineFluoxetine may increase the antiplatelet activities of Mesalazine.Approved
MesoridazineThe risk or severity of QTc prolongation can be increased when Mesoridazine is combined with Fluoxetine.Approved, Investigational
MetahexamideFluoxetine may increase the hypoglycemic activities of Metahexamide.Experimental
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Fluoxetine.Approved
MetergolineThe metabolism of Metergoline can be decreased when combined with Fluoxetine.Experimental
MetforminFluoxetine may increase the hypoglycemic activities of Metformin.Approved
MethacyclineThe risk or severity of adverse effects can be increased when Methacycline is combined with Fluoxetine.Approved, Investigational
MethadoneThe metabolism of Methadone can be decreased when combined with Fluoxetine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Fluoxetine.Approved, Illicit
MethamphetamineThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Fluoxetine.Approved, Illicit
Methanesulfonyl FluorideThe therapeutic efficacy of Fluoxetine can be decreased when used in combination with Methanesulfonyl Fluoride.Investigational
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Fluoxetine.Approved, Investigational
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Fluoxetine.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Fluoxetine.Illicit, Withdrawn
MetharbitalThe risk or severity of adverse effects can be increased when Metharbital is combined with Fluoxetine.Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Fluoxetine.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Fluoxetine.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Fluoxetine.Approved
MethotrimeprazineFluoxetine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Fluoxetine.Approved, Investigational, Vet Approved
MethscopolamineThe risk or severity of adverse effects can be increased when Methscopolamine is combined with Fluoxetine.Approved
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Fluoxetine.Approved
MethyclothiazideThe risk or severity of hyponatremia can be increased when Fluoxetine is combined with Methyclothiazide.Approved
Methylene blueFluoxetine may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylergometrineThe metabolism of Methylergometrine can be decreased when combined with Fluoxetine.Approved
MethylpentynolThe risk or severity of adverse effects can be increased when Methylpentynol is combined with Fluoxetine.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Fluoxetine.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Fluoxetine.Approved, Vet Approved
Methylscopolamine bromideThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Fluoxetine.Approved
MethyprylonThe risk or severity of adverse effects can be increased when Methyprylon is combined with Fluoxetine.Approved, Illicit, Withdrawn
MethysergideThe metabolism of Methysergide can be decreased when combined with Fluoxetine.Approved
MetipranololThe serum concentration of Metipranolol can be increased when it is combined with Fluoxetine.Approved
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Fluoxetine.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Fluoxetine.Approved, Investigational
MetocurineThe risk or severity of adverse effects can be increased when Metocurine is combined with Fluoxetine.Approved
Metocurine IodideThe risk or severity of adverse effects can be increased when Metocurine Iodide is combined with Fluoxetine.Approved, Withdrawn
MetolazoneThe risk or severity of hyponatremia can be increased when Fluoxetine is combined with Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Fluoxetine.Approved, Investigational
MetronidazoleThe risk or severity of QTc prolongation can be increased when Metronidazole is combined with Fluoxetine.Approved
MetyrosineFluoxetine may increase the sedative activities of Metyrosine.Approved
MexiletineThe metabolism of Mexiletine can be decreased when combined with Fluoxetine.Approved, Investigational
MianserinThe risk or severity of adverse effects can be increased when Mianserin is combined with Fluoxetine.Approved, Investigational
MibefradilThe metabolism of Fluoxetine can be decreased when combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe metabolism of Fluoxetine can be decreased when combined with Miconazole.Approved, Investigational, Vet Approved
MicronomicinThe risk or severity of adverse effects can be increased when Micronomicin is combined with Fluoxetine.Experimental
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Fluoxetine.Approved, Illicit
MidomafetamineThe risk or severity of adverse effects can be increased when Midomafetamine is combined with Fluoxetine.Experimental, Illicit, Investigational
MidostaurinThe metabolism of Fluoxetine can be decreased when combined with Midostaurin.Approved, Investigational
MifepristoneThe serum concentration of Fluoxetine can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolFluoxetine may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Milnacipran.Approved, Investigational
MinaprineThe therapeutic efficacy of Fluoxetine can be decreased when used in combination with Minaprine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.Approved, Investigational
MirabegronThe risk or severity of QTc prolongation can be increased when Mirabegron is combined with Fluoxetine.Approved
MirtazapineFluoxetine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitiglinideFluoxetine may increase the hypoglycemic activities of Mitiglinide.Approved, Investigational
MitomycinThe serum concentration of Mitomycin can be increased when it is combined with Fluoxetine.Approved
MitotaneThe serum concentration of Fluoxetine can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Fluoxetine.Approved, Investigational
MivacuriumThe risk or severity of adverse effects can be increased when Mivacurium is combined with Fluoxetine.Approved
MocetinostatThe risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Fluoxetine.Investigational
MoclobemideMoclobemide may increase the serotonergic activities of Fluoxetine.Approved, Investigational
ModafinilThe serum concentration of Fluoxetine can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of QTc prolongation can be increased when Moexipril is combined with Fluoxetine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Fluoxetine.Approved
MoperoneThe risk or severity of adverse effects can be increased when Moperone is combined with Fluoxetine.Experimental
MoricizineThe risk or severity of adverse effects can be increased when Moricizine is combined with Fluoxetine.Approved, Investigational, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Fluoxetine.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Mosapramine is combined with Fluoxetine.Experimental
MoxidectinThe serum concentration of Moxidectin can be increased when it is combined with Fluoxetine.Approved, Investigational, Vet Approved
MoxifloxacinThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Fluoxetine.Approved, Investigational
MRK-409The risk or severity of adverse effects can be increased when MRK-409 is combined with Fluoxetine.Experimental
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Fluoxetine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.Approved, Investigational
NabumetoneFluoxetine may increase the antiplatelet activities of Nabumetone.Approved
NadololThe serum concentration of Nadolol can be increased when it is combined with Fluoxetine.Approved
NadroparinFluoxetine may increase the antiplatelet activities of Nadroparin.Approved, Investigational
NafamostatFluoxetine may increase the antiplatelet activities of Nafamostat.Approved, Investigational
NafcillinThe serum concentration of Fluoxetine can be decreased when it is combined with Nafcillin.Approved, Investigational
NaftopidilFluoxetine may increase the antiplatelet activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Fluoxetine.Approved
Nalidixic AcidThe risk or severity of QTc prolongation can be increased when Nalidixic Acid is combined with Fluoxetine.Approved, Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Fluoxetine.Approved
NaloxoneThe metabolism of Fluoxetine can be decreased when combined with Naloxone.Approved, Vet Approved
NaltrexoneThe risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Fluoxetine.Approved, Investigational, Vet Approved
NaproxenFluoxetine may increase the antiplatelet activities of Naproxen.Approved, Vet Approved
NaratriptanThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Naratriptan.Approved, Investigational
NateglinideFluoxetine may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NBI-6024Fluoxetine may increase the hypoglycemic activities of NBI-6024.Investigational
NeamineThe risk or severity of adverse effects can be increased when Neamine is combined with Fluoxetine.Experimental
NefazodoneThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Nefazodone.Approved, Withdrawn
NefiracetamThe risk or severity of adverse effects can be increased when Nefiracetam is combined with Fluoxetine.Investigational
NelfinavirThe risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Fluoxetine.Approved
NemonoxacinThe risk or severity of QTc prolongation can be increased when Nemonoxacin is combined with Fluoxetine.Investigational
NeocitrullamonThe risk or severity of adverse effects can be increased when Neocitrullamon is combined with Fluoxetine.Experimental
NeomycinThe risk or severity of adverse effects can be increased when Neomycin is combined with Fluoxetine.Approved, Vet Approved
NeosaxitoxinThe risk or severity of adverse effects can be increased when Neosaxitoxin is combined with Fluoxetine.Investigational
NeostigmineThe therapeutic efficacy of Fluoxetine can be decreased when used in combination with Neostigmine.Approved, Vet Approved
NepafenacFluoxetine may increase the antiplatelet activities of Nepafenac.Approved, Investigational
NetilmicinThe risk or severity of adverse effects can be increased when Netilmicin is combined with Fluoxetine.Approved, Investigational
NetoglitazoneFluoxetine may increase the hypoglycemic activities of Netoglitazone.Experimental
NetupitantThe serum concentration of Fluoxetine can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Fluoxetine can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the serotonergic activities of Fluoxetine.Withdrawn
NiaprazineThe risk or severity of adverse effects can be increased when Niaprazine is combined with Fluoxetine.Experimental
NicardipineThe risk or severity of QTc prolongation can be increased when Nicardipine is combined with Fluoxetine.Approved, Investigational
NicergolineThe metabolism of Nicergoline can be decreased when combined with Fluoxetine.Approved, Investigational
NicomorphineThe risk or severity of serotonin syndrome can be increased when Nicomorphine is combined with Fluoxetine.Experimental
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Fluoxetine.Approved
Niflumic AcidThe risk or severity of gastrointestinal bleeding and gastrointestinal ulceration can be increased when Fluoxetine is combined with Niflumic Acid.Approved
NilotinibThe risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Nilotinib.Approved, Investigational
NimesulideFluoxetine may increase the antiplatelet activities of Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Fluoxetine.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Fluoxetine.Approved
NisoxetineThe risk or severity of adverse effects can be increased when Nisoxetine is combined with Fluoxetine.Experimental
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Fluoxetine.Approved
NitroaspirinFluoxetine may increase the antiplatelet activities of Nitroaspirin.Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Fluoxetine.Approved, Vet Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Fluoxetine.Approved
NN344Fluoxetine may increase the hypoglycemic activities of NN344.Investigational
NomifensineThe risk or severity of adverse effects can be increased when Nomifensine is combined with Fluoxetine.Withdrawn
NordazepamThe risk or severity of adverse effects can be increased when Nordazepam is combined with Fluoxetine.Approved
NorfloxacinThe risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Fluoxetine.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Fluoxetine.Approved, Illicit
NortriptylineThe risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Fluoxetine.Approved
OctamoxinOctamoxin may increase the serotonergic activities of Fluoxetine.Withdrawn
OctreotideThe risk or severity of QTc prolongation can be increased when Octreotide is combined with Fluoxetine.Approved, Investigational
OdanacatibThe serum concentration of Odanacatib can be increased when it is combined with Fluoxetine.Investigational
OfloxacinThe risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Fluoxetine.Approved
OlanzapineThe risk or severity of QTc prolongation can be increased when Olanzapine is combined with Fluoxetine.Approved, Investigational
OlaparibThe metabolism of Fluoxetine can be decreased when combined with Olaparib.Approved
OlodaterolThe risk or severity of QTc prolongation can be increased when Olodaterol is combined with Fluoxetine.Approved
OlopatadineThe risk or severity of QTc prolongation can be increased when Olopatadine is combined with Fluoxetine.Approved
OmarigliptinFluoxetine may increase the hypoglycemic activities of Omarigliptin.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Fluoxetine.Approved, Investigational
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Fluoxetine.Approved, Investigational, Vet Approved
OndansetronThe risk or severity of QTc prolongation can be increased when Ondansetron is combined with Fluoxetine.Approved
OpipramolThe risk or severity of adverse effects can be increased when Opipramol is combined with Fluoxetine.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Fluoxetine.Approved, Illicit
OrbifloxacinThe risk or severity of QTc prolongation can be increased when Orbifloxacin is combined with Fluoxetine.Vet Approved
OrphenadrineFluoxetine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OrvepitantThe risk or severity of adverse effects can be increased when Orvepitant is combined with Fluoxetine.Investigational
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Fluoxetine.Investigational
OtamixabanFluoxetine may increase the antiplatelet activities of Otamixaban.Investigational
OtiloniumThe risk or severity of adverse effects can be increased when Otilonium is combined with Fluoxetine.Experimental, Investigational
OxaflozaneThe risk or severity of adverse effects can be increased when Oxaflozane is combined with Fluoxetine.Experimental
OxaliplatinThe risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Fluoxetine.Approved, Investigational
OxaprotilineThe risk or severity of adverse effects can be increased when Oxaprotiline is combined with Fluoxetine.Experimental
OxaprozinFluoxetine may increase the antiplatelet activities of Oxaprozin.Approved
OxatomideThe risk or severity of QTc prolongation can be increased when Oxatomide is combined with Fluoxetine.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Fluoxetine.Approved
OxcarbazepineThe risk or severity of adverse effects can be increased when Oxcarbazepine is combined with Fluoxetine.Approved
OxiracetamThe risk or severity of adverse effects can be increased when Oxiracetam is combined with Fluoxetine.Experimental
OxitriptanThe risk or severity of adverse effects can be increased when Oxitriptan is combined with Fluoxetine.Approved, Investigational, Nutraceutical
OxitropiumThe risk or severity of adverse effects can be increased when Oxitropium is combined with Fluoxetine.Investigational
Oxolinic acidThe risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Fluoxetine.Experimental
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Fluoxetine.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Fluoxetine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Oxypertine is combined with Fluoxetine.Experimental
OxyphencyclimineThe risk or severity of adverse effects can be increased when Oxyphencyclimine is combined with Fluoxetine.Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Fluoxetine.Approved
OxytetracyclineThe risk or severity of adverse effects can be increased when Oxytetracycline is combined with Fluoxetine.Approved, Investigational, Vet Approved
OxytocinThe risk or severity of QTc prolongation can be increased when Oxytocin is combined with Fluoxetine.Approved, Vet Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Fluoxetine.Approved, Vet Approved
PalbociclibThe serum concentration of Fluoxetine can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Paliperidone.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Fluoxetine.Approved, Investigational
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Fluoxetine.Approved
PanobinostatThe serum concentration of Fluoxetine can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Fluoxetine.Approved
PapaverineThe risk or severity of QTc prolongation can be increased when Papaverine is combined with Fluoxetine.Approved, Investigational
ParaldehydeFluoxetine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParamethadioneThe risk or severity of adverse effects can be increased when Paramethadione is combined with Fluoxetine.Approved
ParaoxonThe therapeutic efficacy of Fluoxetine can be decreased when used in combination with Paraoxon.Experimental
ParecoxibThe risk or severity of gastrointestinal bleeding and gastrointestinal ulceration can be increased when Fluoxetine is combined with Parecoxib.Approved
PargylinePargyline may increase the serotonergic activities of Fluoxetine.Approved
ParitaprevirThe serum concentration of Paritaprevir can be increased when it is combined with Fluoxetine.Approved, Investigational
ParnaparinFluoxetine may increase the antiplatelet activities of Parnaparin.Approved, Investigational
ParomomycinThe risk or severity of adverse effects can be increased when Paromomycin is combined with Fluoxetine.Approved, Investigational
ParoxetineThe risk or severity of QTc prolongation can be increased when Paroxetine is combined with Fluoxetine.Approved, Investigational
PasireotideThe risk or severity of QTc prolongation can be increased when Pasireotide is combined with Fluoxetine.Approved
Patent BlueThe therapeutic efficacy of Fluoxetine can be decreased when used in combination with Patent Blue.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Fluoxetine.Approved
PazufloxacinThe risk or severity of QTc prolongation can be increased when Pazufloxacin is combined with Fluoxetine.Investigational
PefloxacinThe risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Fluoxetine.Approved
Peginterferon alfa-2bThe serum concentration of Fluoxetine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololThe serum concentration of Penbutolol can be increased when it is combined with Fluoxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Fluoxetine.Experimental
PenimepicyclineThe risk or severity of adverse effects can be increased when Penimepicycline is combined with Fluoxetine.Experimental
PentamidineThe risk or severity of QTc prolongation can be increased when Pentamidine is combined with Fluoxetine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Fluoxetine.Approved, Vet Approved
PenthienateThe risk or severity of adverse effects can be increased when Penthienate is combined with Fluoxetine.Experimental
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Fluoxetine.Approved, Investigational, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Fluoxetine.Approved
Pentosan PolysulfateFluoxetine may increase the antiplatelet activities of Pentosan Polysulfate.Approved
PentoxifyllineFluoxetine may increase the antiplatelet activities of Pentoxifylline.Approved, Investigational
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Fluoxetine.Approved, Investigational
PerflutrenThe risk or severity of QTc prolongation can be increased when Perflutren is combined with Fluoxetine.Approved
PergolideThe metabolism of Pergolide can be decreased when combined with Fluoxetine.Approved, Investigational, Vet Approved, Withdrawn
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Fluoxetine.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Fluoxetine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Fluoxetine.Approved
PhenacemideThe risk or severity of adverse effects can be increased when Phenacemide is combined with Fluoxetine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Fluoxetine.Experimental
PhencyclidineThe risk or severity of adverse effects can be increased when Phencyclidine is combined with Fluoxetine.Illicit
PhenelzinePhenelzine may increase the serotonergic activities of Fluoxetine.Approved
PhenethylamineThe risk or severity of adverse effects can be increased when Phenethylamine is combined with Fluoxetine.Experimental
PheneturideThe risk or severity of adverse effects can be increased when Pheneturide is combined with Fluoxetine.Experimental
PhenforminFluoxetine may increase the hypoglycemic activities of Phenformin.Approved, Investigational, Withdrawn
PhenglutarimideThe risk or severity of adverse effects can be increased when Phenglutarimide is combined with Fluoxetine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Phenibut is combined with Fluoxetine.Experimental
PhenindioneFluoxetine may increase the antiplatelet activities of Phenindione.Approved, Investigational
PheniprazinePheniprazine may increase the serotonergic activities of Fluoxetine.Withdrawn
PheniramineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Fluoxetine.Approved
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Fluoxetine.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Fluoxetine.Experimental
PhenothiazineThe serum concentration of Phenothiazine can be increased when it is combined with Fluoxetine.Vet Approved
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Fluoxetine.Withdrawn
PhenprobamateThe risk or severity of adverse effects can be increased when Phenprobamate is combined with Fluoxetine.Experimental
PhenprocoumonFluoxetine may increase the antiplatelet activities of Phenprocoumon.Approved, Investigational
PhensuximideThe risk or severity of adverse effects can be increased when Phensuximide is combined with Fluoxetine.Approved
PhenylbutazoneFluoxetine may increase the antiplatelet activities of Phenylbutazone.Approved, Vet Approved
Phenylbutyric acidThe metabolism of Fluoxetine can be decreased when combined with Phenylbutyric acid.Approved, Investigational
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Fluoxetine.Approved, Vet Approved
PhysostigmineThe therapeutic efficacy of Fluoxetine can be decreased when used in combination with Physostigmine.Approved, Investigational
PibrentasvirThe serum concentration of Pibrentasvir can be increased when it is combined with Fluoxetine.Approved, Investigational
PicotamideFluoxetine may increase the antiplatelet activities of Picotamide.Experimental
PimavanserinThe risk or severity of adverse effects can be increased when Pimavanserin is combined with Fluoxetine.Approved, Investigational
PimozideFluoxetine may increase the QTc-prolonging activities of Pimozide.Approved
PinazepamThe risk or severity of adverse effects can be increased when Pinazepam is combined with Fluoxetine.Experimental
PindololThe serum concentration of Pindolol can be increased when it is combined with Fluoxetine.Approved, Investigational
PioglitazoneFluoxetine may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Fluoxetine.Approved, Investigational
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Fluoxetine.Approved
Pipemidic acidThe risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Fluoxetine.Experimental
PipenzolateThe risk or severity of adverse effects can be increased when Pipenzolate is combined with Fluoxetine.Experimental
PiperidolateThe risk or severity of adverse effects can be increased when Piperidolate is combined with Fluoxetine.Experimental
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Fluoxetine.Approved, Investigational
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Fluoxetine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Fluoxetine.Approved, Investigational
PirlimycinThe risk or severity of adverse effects can be increased when Pirlimycin is combined with Fluoxetine.Vet Approved
PirlindolePirlindole may increase the serotonergic activities of Fluoxetine.Approved
Piromidic acidThe risk or severity of QTc prolongation can be increased when Piromidic acid is combined with Fluoxetine.Experimental
PiroxicamFluoxetine may increase the antiplatelet activities of Piroxicam.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Fluoxetine.Approved
PitolisantThe serum concentration of Pitolisant can be increased when it is combined with Fluoxetine.Approved, Investigational
PivagabineThe risk or severity of adverse effects can be increased when Pivagabine is combined with Fluoxetine.Investigational
PivhydrazinePivhydrazine may increase the serotonergic activities of Fluoxetine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Fluoxetine.Approved
PlazomicinThe risk or severity of adverse effects can be increased when Plazomicin is combined with Fluoxetine.Approved, Investigational
PoldineThe risk or severity of adverse effects can be increased when Poldine is combined with Fluoxetine.Experimental
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when Polymyxin B Sulfate is combined with Fluoxetine.Approved, Vet Approved
PolythiazideThe risk or severity of hyponatremia can be increased when Fluoxetine is combined with Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Fluoxetine.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Fluoxetine.Approved, Investigational
PosaconazoleThe risk or severity of QTc prolongation can be increased when Posaconazole is combined with Fluoxetine.Approved, Investigational, Vet Approved
Potassium CitrateFluoxetine may increase the antiplatelet activities of Potassium Citrate.Approved, Investigational, Vet Approved
PracinostatThe risk or severity of QTc prolongation can be increased when Pracinostat is combined with Fluoxetine.Investigational
PractololThe serum concentration of Practolol can be increased when it is combined with Fluoxetine.Approved
PramipexoleFluoxetine may increase the sedative activities of Pramipexole.Approved, Investigational
PramlintideFluoxetine may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrasugrelFluoxetine may increase the antiplatelet activities of Prasugrel.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Fluoxetine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Fluoxetine.Approved, Illicit
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Fluoxetine.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Fluoxetine.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Fluoxetine.Approved, Vet Approved
PregabalinThe therapeutic efficacy of Fluoxetine can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PridinolThe risk or severity of adverse effects can be increased when Pridinol is combined with Fluoxetine.Experimental
PrifiniumThe risk or severity of adverse effects can be increased when Prifinium is combined with Fluoxetine.Experimental
PrimaquineThe risk or severity of QTc prolongation can be increased when Primaquine is combined with Fluoxetine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Fluoxetine.Approved, Vet Approved
ProbucolThe risk or severity of QTc prolongation can be increased when Probucol is combined with Fluoxetine.Approved, Investigational
ProcainamideThe risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Fluoxetine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Fluoxetine.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fluoxetine.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Fluoxetine.Approved
ProgabideThe risk or severity of adverse effects can be increased when Progabide is combined with Fluoxetine.Approved, Investigational
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Fluoxetine.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Fluoxetine.Approved
PromazineThe risk or severity of QTc prolongation can be increased when Promazine is combined with Fluoxetine.Approved, Vet Approved
PromethazineThe risk or severity of QTc prolongation can be increased when Promethazine is combined with Fluoxetine.Approved, Investigational
PropafenonePropafenone may increase the QTc-prolonging activities of Fluoxetine.Approved
PropanididThe risk or severity of adverse effects can be increased when Propanidid is combined with Fluoxetine.Experimental
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Fluoxetine.Approved
PropericiazineThe risk or severity of adverse effects can be increased when Propericiazine is combined with Fluoxetine.Approved, Investigational
PropiomazineThe risk or severity of adverse effects can be increased when Propiomazine is combined with Fluoxetine.Approved
PropiopromazineThe risk or severity of adverse effects can be increased when Propiopromazine is combined with Fluoxetine.Vet Approved
PropiverineThe risk or severity of adverse effects can be increased when Propiverine is combined with Fluoxetine.Approved, Investigational
PropofolThe risk or severity of QTc prolongation can be increased when Propofol is combined with Fluoxetine.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Fluoxetine.Approved, Investigational
Protein CFluoxetine may increase the antiplatelet activities of Protein C.Approved
Protein S humanFluoxetine may increase the antiplatelet activities of Protein S human.Approved
ProthipendylThe risk or severity of adverse effects can be increased when Prothipendyl is combined with Fluoxetine.Investigational
ProtocatechualdehydeFluoxetine may increase the antiplatelet activities of Protocatechualdehyde.Approved
ProtriptylineThe risk or severity of QTc prolongation can be increased when Protriptyline is combined with Fluoxetine.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Proxibarbal is combined with Fluoxetine.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Fluoxetine.Approved
PrulifloxacinThe risk or severity of QTc prolongation can be increased when Prulifloxacin is combined with Fluoxetine.Investigational
PseudoephedrineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Fluoxetine.Approved
PsilocybineThe risk or severity of adverse effects can be increased when Psilocybine is combined with Fluoxetine.Investigational
PuromycinThe risk or severity of adverse effects can be increased when Puromycin is combined with Fluoxetine.Experimental
PyrantelThe risk or severity of adverse effects can be increased when Pyrantel is combined with Fluoxetine.Approved, Vet Approved
PyridostigmineThe therapeutic efficacy of Fluoxetine can be decreased when used in combination with Pyridostigmine.Approved, Investigational
PyrithyldioneThe risk or severity of adverse effects can be increased when Pyrithyldione is combined with Fluoxetine.Experimental
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Fluoxetine.Approved, Illicit
QuetiapineThe risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Quetiapine.Approved
QuinethazoneThe risk or severity of hyponatremia can be increased when Fluoxetine is combined with Quinethazone.Approved
QuinidineThe risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Quinidine.Approved, Investigational
QuinineThe risk or severity of QTc prolongation can be increased when Quinine is combined with Fluoxetine.Approved
QuinupramineThe risk or severity of adverse effects can be increased when Quinupramine is combined with Fluoxetine.Experimental
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Fluoxetine.Approved, Investigational
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Fluoxetine.Investigational
RamatrobanFluoxetine may increase the antiplatelet activities of Ramatroban.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Fluoxetine.Approved, Investigational
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Fluoxetine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Fluoxetine.Approved, Investigational
RapacuroniumThe risk or severity of adverse effects can be increased when Rapacuronium is combined with Fluoxetine.Withdrawn
RasagilineRasagiline may increase the serotonergic activities of Fluoxetine.Approved
ReboxetineThe risk or severity of adverse effects can be increased when Reboxetine is combined with Fluoxetine.Approved, Investigational
RegorafenibThe serum concentration of Regorafenib can be increased when it is combined with Fluoxetine.Approved
RelcovaptanFluoxetine may increase the antiplatelet activities of Relcovaptan.Investigational
RemacemideThe risk or severity of adverse effects can be increased when Remacemide is combined with Fluoxetine.Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Fluoxetine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Fluoxetine.Approved, Withdrawn
RepaglinideFluoxetine may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
ReposalThe risk or severity of adverse effects can be increased when Reposal is combined with Fluoxetine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Fluoxetine.Approved, Investigational
ResveratrolFluoxetine may increase the antiplatelet activities of Resveratrol.Approved, Experimental, Investigational
ReteplaseFluoxetine may increase the antiplatelet activities of Reteplase.Approved, Investigational
RevefenacinThe risk or severity of adverse effects can be increased when Revefenacin is combined with Fluoxetine.Investigational
ReviparinFluoxetine may increase the antiplatelet activities of Reviparin.Approved, Investigational
RheinThe metabolism of Fluoxetine can be decreased when combined with Rhein.Experimental
Rhodamine 6GThe serum concentration of Rhodamine 6G can be increased when it is combined with Fluoxetine.Experimental
RibociclibThe risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Ribociclib.Approved, Investigational
RibostamycinThe risk or severity of adverse effects can be increased when Ribostamycin is combined with Fluoxetine.Approved, Investigational
RicolinostatThe risk or severity of QTc prolongation can be increased when Ricolinostat is combined with Fluoxetine.Investigational
RidogrelFluoxetine may increase the antiplatelet activities of Ridogrel.Approved
RifampicinThe metabolism of Fluoxetine can be increased when combined with Rifampicin.Approved
RifamycinThe metabolism of Fluoxetine can be increased when combined with Rifamycin.Investigational
RifapentineThe metabolism of Fluoxetine can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Fluoxetine.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Fluoxetine.Approved
RiluzoleThe risk or severity of adverse effects can be increased when Riluzole is combined with Fluoxetine.Approved, Investigational
RimexoloneThe metabolism of Fluoxetine can be increased when combined with Rimexolone.Approved
RisperidoneThe metabolism of Risperidone can be decreased when combined with Fluoxetine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ritanserin is combined with Fluoxetine.Investigational
RitonavirThe risk or severity of QTc prolongation can be increased when Ritonavir is combined with Fluoxetine.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Fluoxetine.Approved
RivastigmineThe therapeutic efficacy of Fluoxetine can be decreased when used in combination with Rivastigmine.Approved, Investigational
RivoglitazoneFluoxetine may increase the hypoglycemic activities of Rivoglitazone.Experimental, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Rizatriptan.Approved
RobenacoxibThe risk or severity of gastrointestinal bleeding and gastrointestinal ulceration can be increased when Fluoxetine is combined with Robenacoxib.Experimental, Vet Approved
RociverineThe risk or severity of adverse effects can be increased when Rociverine is combined with Fluoxetine.Experimental
RocuroniumThe risk or severity of adverse effects can be increased when Rocuronium is combined with Fluoxetine.Approved
RofecoxibThe risk or severity of gastrointestinal bleeding and gastrointestinal ulceration can be increased when Fluoxetine is combined with Rofecoxib.Approved, Investigational, Withdrawn
RolapitantThe metabolism of Fluoxetine can be decreased when combined with Rolapitant.Approved, Investigational
RolipramThe risk or severity of adverse effects can be increased when Rolipram is combined with Fluoxetine.Investigational
RolitetracyclineThe risk or severity of adverse effects can be increased when Rolitetracycline is combined with Fluoxetine.Approved
RomidepsinThe risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Romidepsin.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Fluoxetine.Vet Approved
RopiniroleFluoxetine may increase the sedative activities of Ropinirole.Approved, Investigational
RosiglitazoneFluoxetine may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
RosoxacinThe risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Fluoxetine.Approved, Investigational
RotigotineFluoxetine may increase the sedative activities of Rotigotine.Approved
RoxithromycinThe risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Fluoxetine.Approved, Investigational, Withdrawn
RP-5063The risk or severity of adverse effects can be increased when RP-5063 is combined with Fluoxetine.Investigational
RucaparibThe serum concentration of Rucaparib can be increased when it is combined with Fluoxetine.Approved, Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Fluoxetine.Approved
RufloxacinThe risk or severity of QTc prolongation can be increased when Rufloxacin is combined with Fluoxetine.Experimental
RupatadineThe risk or severity of QTc prolongation can be increased when Rupatadine is combined with Fluoxetine.Approved
SafinamideSafinamide may increase the serotonergic activities of Fluoxetine.Approved, Investigational
SafrazineSafrazine may increase the serotonergic activities of Fluoxetine.Withdrawn
SalbutamolThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Fluoxetine.Approved, Vet Approved
Salicylic acidFluoxetine may increase the antiplatelet activities of Salicylic acid.Approved, Investigational, Vet Approved
SalmeterolThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Fluoxetine.Approved
SalsalateFluoxetine may increase the antiplatelet activities of Salsalate.Approved
SaquinavirThe risk or severity of QTc prolongation can be increased when Saquinavir is combined with Fluoxetine.Approved, Investigational
SarafloxacinThe risk or severity of QTc prolongation can be increased when Sarafloxacin is combined with Fluoxetine.Vet Approved, Withdrawn
SaredutantThe risk or severity of adverse effects can be increased when Saredutant is combined with Fluoxetine.Investigational
SarilumabThe therapeutic efficacy of Fluoxetine can be decreased when used in combination with Sarilumab.Approved, Investigational
SarpogrelateFluoxetine may increase the antiplatelet activities of Sarpogrelate.Investigational
SaruplaseFluoxetine may increase the antiplatelet activities of Saruplase.Experimental
SaxagliptinFluoxetine may increase the hypoglycemic activities of Saxagliptin.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Fluoxetine.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Fluoxetine.Approved, Vet Approved
Secretin humanThe therapeutic efficacy of Secretin human can be decreased when used in combination with Fluoxetine.Approved
Secretin porcineThe therapeutic efficacy of Secretin porcine can be decreased when used in combination with Fluoxetine.Approved
SelegilineSelegiline may increase the serotonergic activities of Fluoxetine.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Fluoxetine.Approved
SemaglutideFluoxetine may increase the hypoglycemic activities of Semaglutide.Approved, Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Fluoxetine.Approved, Investigational, Withdrawn
SertralineThe risk or severity of QTc prolongation can be increased when Sertraline is combined with Fluoxetine.Approved
SevofluraneThe risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Fluoxetine.Approved, Vet Approved
SibutramineThe risk or severity of adverse effects can be increased when Sibutramine is combined with Fluoxetine.Approved, Illicit, Investigational, Withdrawn
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Fluoxetine.Approved
SiltuximabThe serum concentration of Fluoxetine can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Fluoxetine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Fluoxetine.Approved
SirolimusThe serum concentration of Sirolimus can be increased when it is combined with Fluoxetine.Approved, Investigational
SisomicinThe risk or severity of adverse effects can be increased when Sisomicin is combined with Fluoxetine.Investigational
SitafloxacinThe risk or severity of QTc prolongation can be increased when Sitafloxacin is combined with Fluoxetine.Experimental, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Fluoxetine.Approved, Investigational
Sodium CitrateFluoxetine may increase the antiplatelet activities of Sodium Citrate.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Fluoxetine.Approved
SolifenacinThe risk or severity of QTc prolongation can be increased when Solifenacin is combined with Fluoxetine.Approved
SomatostatinThe serum concentration of Somatostatin can be increased when it is combined with Fluoxetine.Approved, Investigational
SorafenibThe risk or severity of QTc prolongation can be increased when Sorafenib is combined with Fluoxetine.Approved, Investigational
SotagliflozinFluoxetine may increase the hypoglycemic activities of Sotagliflozin.Investigational
SotalolThe risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Sotalol.Approved
SparfloxacinThe risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Sparfloxacin.Approved, Investigational
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Fluoxetine.Experimental
St. John's WortThe serum concentration of Fluoxetine can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StanoloneThe serum concentration of Stanolone can be increased when it is combined with Fluoxetine.Illicit, Investigational
Stanolone acetateThe serum concentration of Stanolone acetate can be increased when it is combined with Fluoxetine.Experimental
StiripentolThe serum concentration of Fluoxetine can be increased when it is combined with Stiripentol.Approved
StreptokinaseFluoxetine may increase the antiplatelet activities of Streptokinase.Approved, Investigational
StreptomycinThe risk or severity of adverse effects can be increased when Streptomycin is combined with Fluoxetine.Approved, Vet Approved
StyramateThe risk or severity of adverse effects can be increased when Styramate is combined with Fluoxetine.Experimental
SuccinylcholineThe risk or severity of adverse effects can be increased when Succinylcholine is combined with Fluoxetine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Fluoxetine.Approved, Investigational
SulconazoleThe metabolism of Fluoxetine can be decreased when combined with Sulconazole.Approved
SulfadiazineFluoxetine may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleThe risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Fluoxetine.Approved
SulfasalazineFluoxetine may increase the antiplatelet activities of Sulfasalazine.Approved
SulfinpyrazoneFluoxetine may increase the antiplatelet activities of Sulfinpyrazone.Approved
SulfisoxazoleThe risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Fluoxetine.Approved, Vet Approved
SulindacFluoxetine may increase the antiplatelet activities of Sulindac.Approved, Investigational
SulodexideFluoxetine may increase the antiplatelet activities of Sulodexide.Approved, Investigational
SulpirideThe risk or severity of QTc prolongation can be increased when Sulpiride is combined with Fluoxetine.Approved, Investigational
SulthiameThe risk or severity of adverse effects can be increased when Sulthiame is combined with Fluoxetine.Experimental
SultoprideThe risk or severity of QTc prolongation can be increased when Sultopride is combined with Fluoxetine.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Sumatriptan.Approved, Investigational
SunitinibThe risk or severity of QTc prolongation can be increased when Sunitinib is combined with Fluoxetine.Approved, Investigational
SuprofenFluoxetine may increase the antiplatelet activities of Suprofen.Approved, Withdrawn
SuvorexantFluoxetine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TacrineThe therapeutic efficacy of Fluoxetine can be decreased when used in combination with Tacrine.Investigational, Withdrawn
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Fluoxetine.Approved, Investigational
TafenoquineThe metabolism of Tafenoquine can be decreased when combined with Fluoxetine.Approved, Investigational
TalbutalThe risk or severity of adverse effects can be increased when Talbutal is combined with Fluoxetine.Approved, Illicit
TalinololThe serum concentration of Talinolol can be increased when it is combined with Fluoxetine.Investigational
TalniflumateThe risk or severity of gastrointestinal bleeding and gastrointestinal ulceration can be increased when Fluoxetine is combined with Talniflumate.Approved
TalopramThe risk or severity of adverse effects can be increased when Talopram is combined with Fluoxetine.Experimental
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Fluoxetine.Approved
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Fluoxetine.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Fluoxetine.Investigational
TandutinibThe risk or severity of QTc prolongation can be increased when Tandutinib is combined with Fluoxetine.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Fluoxetine.Approved, Investigational
TaspoglutideFluoxetine may increase the hypoglycemic activities of Taspoglutide.Investigational
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Fluoxetine.Experimental
Technetium Tc-99m ciprofloxacinThe risk or severity of QTc prolongation can be increased when Technetium Tc-99m ciprofloxacin is combined with Fluoxetine.Investigational
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Fluoxetine.Approved, Investigational
Tedizolid phosphateTedizolid phosphate may increase the serotonergic activities of Fluoxetine.Approved
TelaprevirThe metabolism of Fluoxetine can be decreased when combined with Telaprevir.Approved, Withdrawn
TelavancinThe risk or severity of QTc prolongation can be increased when Telavancin is combined with Fluoxetine.Approved
TelithromycinThe risk or severity of QTc prolongation can be increased when Telithromycin is combined with Fluoxetine.Approved
TemafloxacinThe risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Temafloxacin.Withdrawn
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Fluoxetine.Approved, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Fluoxetine.Approved
TenecteplaseFluoxetine may increase the antiplatelet activities of Tenecteplase.Approved
TeneligliptinFluoxetine may increase the hypoglycemic activities of Teneligliptin.Investigational
TeniposideThe serum concentration of Teniposide can be increased when it is combined with Fluoxetine.Approved
TenoxicamFluoxetine may increase the antiplatelet activities of Tenoxicam.Approved
TerbinafineThe metabolism of Fluoxetine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineThe risk or severity of QTc prolongation can be increased when Terbutaline is combined with Fluoxetine.Approved
TerfenadineThe risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Terfenadine.Approved, Withdrawn
TergurideThe metabolism of Terguride can be decreased when combined with Fluoxetine.Experimental
TeriflunomideThe serum concentration of Fluoxetine can be decreased when it is combined with Teriflunomide.Approved
TerlipressinThe risk or severity of QTc prolongation can be increased when Terlipressin is combined with Fluoxetine.Approved, Investigational
TerodilineThe risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Terodiline.Experimental
TertatololThe serum concentration of Tertatolol can be increased when it is combined with Fluoxetine.Experimental
TesmilifeneFluoxetine may increase the antiplatelet activities of Tesmilifene.Investigational
Testosterone propionateThe serum concentration of Testosterone propionate can be increased when it is combined with Fluoxetine.Approved, Investigational, Vet Approved, Withdrawn
TetrabenazineThe serum concentration of Tetrabenazine can be increased when it is combined with Fluoxetine.Approved, Investigational
TetracyclineThe risk or severity of adverse effects can be increased when Tetracycline is combined with Fluoxetine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Fluoxetine.Investigational
TetrazepamThe risk or severity of adverse effects can be increased when Tetrazepam is combined with Fluoxetine.Experimental
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Fluoxetine.Investigational
ThalidomideFluoxetine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Fluoxetine can be decreased when combined with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Fluoxetine.Approved, Vet Approved
ThiazinamThe risk or severity of adverse effects can be increased when Thiazinam is combined with Fluoxetine.Experimental
ThiethylperazineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Fluoxetine.Withdrawn
ThiocolchicosideThe risk or severity of adverse effects can be increased when Thiocolchicoside is combined with Fluoxetine.Approved, Investigational
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Fluoxetine.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Thiopropazate is combined with Fluoxetine.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Thioproperazine is combined with Fluoxetine.Approved
ThioridazineFluoxetine may increase the QTc-prolonging activities of Thioridazine.Approved, Withdrawn
ThiothixeneThe risk or severity of QTc prolongation can be increased when Thiothixene is combined with Fluoxetine.Approved
ThonzylamineThe risk or severity of adverse effects can be increased when Thonzylamine is combined with Fluoxetine.Approved
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Fluoxetine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Fluoxetine.Approved, Investigational
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Fluoxetine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Fluoxetine.Approved, Investigational
Tiaprofenic acidFluoxetine may increase the antiplatelet activities of Tiaprofenic acid.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Fluoxetine.Approved
TiclopidineFluoxetine may increase the antiplatelet activities of Ticlopidine.Approved
Tiemonium iodideThe risk or severity of adverse effects can be increased when Tiemonium iodide is combined with Fluoxetine.Experimental
TigecyclineThe risk or severity of adverse effects can be increased when Tigecycline is combined with Fluoxetine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Fluoxetine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Fluoxetine.Experimental
TimepidiumThe risk or severity of adverse effects can be increased when Timepidium is combined with Fluoxetine.Experimental
TimololThe serum concentration of Timolol can be increased when it is combined with Fluoxetine.Approved
TinzaparinFluoxetine may increase the antiplatelet activities of Tinzaparin.Approved
TioclomarolFluoxetine may increase the antiplatelet activities of Tioclomarol.Experimental
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Fluoxetine.Approved
TipranavirThe metabolism of Fluoxetine can be decreased when combined with Tipranavir.Approved, Investigational
TirofibanFluoxetine may increase the antiplatelet activities of Tirofiban.Approved
TizanidineThe risk or severity of QTc prolongation can be increased when Tizanidine is combined with Fluoxetine.Approved, Investigational
TobramycinThe risk or severity of adverse effects can be increased when Tobramycin is combined with Fluoxetine.Approved, Investigational
TocilizumabThe serum concentration of Fluoxetine can be decreased when it is combined with Tocilizumab.Approved
TocopherylquinoneFluoxetine may increase the antiplatelet activities of Tocopherylquinone.Experimental, Investigational
TofisopamThe risk or severity of adverse effects can be increased when Tofisopam is combined with Fluoxetine.Approved
TolazamideFluoxetine may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolbutamideFluoxetine may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Fluoxetine.Approved, Withdrawn
TolmetinFluoxetine may increase the antiplatelet activities of Tolmetin.Approved
ToloxatoneToloxatone may increase the serotonergic activities of Fluoxetine.Approved
TolperisoneThe risk or severity of adverse effects can be increased when Tolperisone is combined with Fluoxetine.Approved, Investigational
TolterodineThe risk or severity of QTc prolongation can be increased when Tolterodine is combined with Fluoxetine.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Fluoxetine.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Fluoxetine.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Fluoxetine.Approved, Investigational
TorasemideThe metabolism of Torasemide can be decreased when combined with Fluoxetine.Approved
ToremifeneThe risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Toremifene.Approved, Investigational
TramadolFluoxetine may increase the neuroexcitatory activities of Tramadol.Approved, Investigational
TramiprosateThe risk or severity of adverse effects can be increased when Tramiprosate is combined with Fluoxetine.Investigational
TranilastFluoxetine may increase the antiplatelet activities of Tranilast.Approved, Investigational
TranylcypromineTranylcypromine may increase the serotonergic activities of Fluoxetine.Approved, Investigational
TrapidilFluoxetine may increase the antiplatelet activities of Trapidil.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Fluoxetine.Approved, Investigational
TrazodoneThe risk or severity of QTc prolongation can be increased when Trazodone is combined with Fluoxetine.Approved, Investigational
TreprostinilThe risk or severity of QTc prolongation can be increased when Treprostinil is combined with Fluoxetine.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Fluoxetine.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Fluoxetine.Vet Approved
TrichlorfonThe therapeutic efficacy of Fluoxetine can be decreased when used in combination with Trichlorfon.Vet Approved
TrichlormethiazideThe risk or severity of hyponatremia can be increased when Fluoxetine is combined with Trichlormethiazide.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trichloroethylene is combined with Fluoxetine.Approved
TriclofosThe risk or severity of adverse effects can be increased when Triclofos is combined with Fluoxetine.Withdrawn
TridihexethylThe risk or severity of adverse effects can be increased when Tridihexethyl is combined with Fluoxetine.Withdrawn
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Fluoxetine.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Trifluperidol is combined with Fluoxetine.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Fluoxetine.Approved, Vet Approved
TriflusalFluoxetine may increase the antiplatelet activities of Triflusal.Approved, Investigational
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Fluoxetine.Approved
TrimebutineThe risk or severity of adverse effects can be increased when Trimebutine is combined with Fluoxetine.Approved
TrimethadioneThe risk or severity of adverse effects can be increased when Trimethadione is combined with Fluoxetine.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Fluoxetine.Approved, Investigational
TrimethoprimThe risk or severity of QTc prolongation can be increased when Trimethoprim is combined with Fluoxetine.Approved, Vet Approved
TrimipramineThe risk or severity of QTc prolongation can be increased when Trimipramine is combined with Fluoxetine.Approved
TriprolidineThe risk or severity of QTc prolongation can be increased when Triprolidine is combined with Fluoxetine.Approved
TriptorelinThe risk or severity of QTc prolongation can be increased when Triptorelin is combined with Fluoxetine.Approved, Vet Approved
TroglitazoneFluoxetine may increase the hypoglycemic activities of Troglitazone.Investigational, Withdrawn
Trolamine salicylateFluoxetine may increase the antiplatelet activities of Trolamine salicylate.Approved
TroleandomycinThe metabolism of Fluoxetine can be decreased when combined with Troleandomycin.Approved
TropatepineThe risk or severity of adverse effects can be increased when Tropatepine is combined with Fluoxetine.Experimental
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Fluoxetine.Approved, Investigational
TropisetronTropisetron may increase the serotonergic activities of Fluoxetine.Approved, Investigational
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Fluoxetine.Approved
TrovafloxacinThe risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinFluoxetine may increase the antiplatelet activities of Troxerutin.Investigational
TubocurarineThe therapeutic efficacy of Fluoxetine can be decreased when used in combination with Tubocurarine.Approved
TucidinostatThe risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Fluoxetine.Investigational
TyrothricinThe therapeutic efficacy of Fluoxetine can be decreased when used in combination with Tyrothricin.Approved
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Fluoxetine.Approved, Investigational, Nutraceutical
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Fluoxetine.Approved
UrokinaseFluoxetine may increase the antiplatelet activities of Urokinase.Approved, Investigational, Withdrawn
ValdecoxibThe risk or severity of gastrointestinal bleeding and gastrointestinal ulceration can be increased when Fluoxetine is combined with Valdecoxib.Approved, Investigational, Withdrawn
ValerianThe risk or severity of adverse effects can be increased when Valerian is combined with Fluoxetine.Approved, Experimental, Investigational
ValinomycinThe serum concentration of Valinomycin can be increased when it is combined with Fluoxetine.Experimental
ValnoctamideThe risk or severity of adverse effects can be increased when Valnoctamide is combined with Fluoxetine.Investigational
Valproic AcidThe risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Valproic Acid.Approved, Investigational
ValpromideThe risk or severity of adverse effects can be increased when Valpromide is combined with Fluoxetine.Experimental
ValspodarThe serum concentration of Valspodar can be increased when it is combined with Fluoxetine.Investigational
VancomycinThe risk or severity of adverse effects can be increased when Vancomycin is combined with Fluoxetine.Approved
VandetanibThe risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Vandetanib.Approved
VardenafilThe risk or severity of QTc prolongation can be increased when Vardenafil is combined with Fluoxetine.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Fluoxetine.Approved
VelpatasvirThe serum concentration of Velpatasvir can be increased when it is combined with Fluoxetine.Approved, Investigational
VemurafenibThe serum concentration of Fluoxetine can be increased when it is combined with Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Fluoxetine.Approved, Investigational
VenlafaxineThe risk or severity of QTc prolongation can be increased when Venlafaxine is combined with Fluoxetine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Veralipride is combined with Fluoxetine.Experimental
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Fluoxetine.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Fluoxetine.Approved
VilanterolThe risk or severity of QTc prolongation can be increased when Vilanterol is combined with Fluoxetine.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Fluoxetine.Approved
VildagliptinFluoxetine may increase the hypoglycemic activities of Vildagliptin.Approved, Investigational
ViloxazineThe risk or severity of adverse effects can be increased when Viloxazine is combined with Fluoxetine.Approved, Investigational, Withdrawn
VinbarbitalThe risk or severity of adverse effects can be increased when Vinbarbital is combined with Fluoxetine.Experimental
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Fluoxetine.Approved
VincristineThe excretion of Vincristine can be decreased when combined with Fluoxetine.Approved, Investigational
VinflunineThe serum concentration of Vinflunine can be increased when it is combined with Fluoxetine.Approved, Investigational
VinorelbineThe serum concentration of Vinorelbine can be increased when it is combined with Fluoxetine.Approved, Investigational
VinpocetineThe risk or severity of adverse effects can be increased when Vinpocetine is combined with Fluoxetine.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Vinyl ether is combined with Fluoxetine.Experimental
VinylbitalThe risk or severity of adverse effects can be increased when Vinylbital is combined with Fluoxetine.Experimental
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Fluoxetine.Approved, Investigational
VogliboseFluoxetine may increase the hypoglycemic activities of Voglibose.Approved, Investigational
VorapaxarFluoxetine may increase the antiplatelet activities of Vorapaxar.Approved
VoriconazoleThe risk or severity of QTc prolongation can be increased when Voriconazole is combined with Fluoxetine.Approved, Investigational
VorinostatThe risk or severity of QTc prolongation can be increased when Vorinostat is combined with Fluoxetine.Approved, Investigational
VortioxetineThe serum concentration of Vortioxetine can be increased when it is combined with Fluoxetine.Approved, Investigational
VoxilaprevirThe serum concentration of Voxilaprevir can be increased when it is combined with Fluoxetine.Approved, Investigational
WarfarinThe metabolism of Warfarin can be decreased when combined with Fluoxetine.Approved
XimelagatranFluoxetine may increase the antiplatelet activities of Ximelagatran.Approved, Investigational, Withdrawn
XP19986The risk or severity of adverse effects can be increased when XP19986 is combined with Fluoxetine.Investigational
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Fluoxetine.Vet Approved
ZafirlukastThe metabolism of Fluoxetine can be decreased when combined with Zafirlukast.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Fluoxetine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Fluoxetine.Approved
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Fluoxetine.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Zimelidine.Withdrawn
ZiprasidoneFluoxetine may increase the QTc-prolonging activities of Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Fluoxetine.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Zolmitriptan.Approved, Investigational
ZolpidemFluoxetine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Fluoxetine.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Fluoxetine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Fluoxetine.Approved, Investigational, Withdrawn
ZucapsaicinThe metabolism of Fluoxetine can be decreased when combined with Zucapsaicin.Approved, Investigational
ZuclopenthixolThe risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take with food to reduce irritation and nausea.

References

Synthesis Reference

Eduard Schwartz, Joseph Kaspi, Zinovi Itov, Gidon Pilarski, "Production of fluoxetine and new intermediates." U.S. Patent US5225585, issued October, 1990.

US5225585
General References
  1. Wong DT, Bymaster FP, Engleman EA: Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. Life Sci. 1995;57(5):411-41. [PubMed:7623609]
  2. Wong DT, Horng JS, Bymaster FP, Hauser KL, Molloy BB: A selective inhibitor of serotonin uptake: Lilly 110140, 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine. Life Sci. 1974 Aug 1;15(3):471-9. [PubMed:4549929]
  3. Carlsson A, Wong DT: Correction: a note on the discovery of selective serotonin reuptake inhibitors. Life Sci. 1997;61(12):1203. [PubMed:9315511]
  4. Gerber PE, Lynd LD: Selective serotonin-reuptake inhibitor-induced movement disorders. Ann Pharmacother. 1998 Jun;32(6):692-8. [PubMed:9640489]
  5. Caley CF: Extrapyramidal reactions and the selective serotonin-reuptake inhibitors. Ann Pharmacother. 1997 Dec;31(12):1481-9. [PubMed:9416386]
External Links
Human Metabolome Database
HMDB0014615
KEGG Drug
D00823
PubChem Compound
3386
PubChem Substance
46507902
ChemSpider
3269
BindingDB
30130
ChEBI
86990
ChEMBL
CHEMBL41
Therapeutic Targets Database
DAP000186
PharmGKB
PA449673
IUPHAR
203
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Fluoxetine
ATC Codes
N06CA03 — Fluoxetine and psycholepticsN06AB03 — Fluoxetine
AHFS Codes
  • 28:16.04.20 — Selective-serotonin Reuptake Inhibitors
FDA label
Download (194 KB)
MSDS
Download (76.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Not Yet RecruitingPreventionCognitive Dysfunctions1
0RecruitingOtherDiabetes, Diabetes Mellitus Type 11
0RecruitingTreatmentDiabetes, Diabetes Mellitus Type 1 / Hypoglycemia Associated Autonomic Failure1
1CompletedNot AvailableHealthy Volunteers4
1CompletedTreatmentCancer, Advanced / Obese experiencing rapid weight loss1
1CompletedTreatmentDepression2
1CompletedTreatmentHealthy Volunteers2
1CompletedTreatmentMajor Depressive Disorder (MDD)2
1, 2CompletedHealth Services ResearchAdolescent Depression2
1, 2CompletedTreatmentHypochondriasis1
1, 2RecruitingTreatmentSyndrome X1
2Active Not RecruitingTreatmentSecondary Progressive Multiple Sclerosis (SPMS)1
2CompletedSupportive CareMultiple System Atrophy (MSA)1
2CompletedTreatmentAlcoholism / Depression1
2CompletedTreatmentAnxiety Disorders / Depression / Lung Cancers / Tiredness1
2CompletedTreatmentAutistic Disorder1
2CompletedTreatmentBack Pain / Sciatica1
2CompletedTreatmentCannabis Abuse / Major Depressive Disorder (MDD)1
2CompletedTreatmentCocaine-Related Disorders1
2CompletedTreatmentDepression1
2CompletedTreatmentDepression / Human Immunodeficiency Virus (HIV) Infections1
2CompletedTreatmentDomestic Violence1
2CompletedTreatmentFibromyalgia / Growth Hormone Deficiency (GHD)1
2CompletedTreatmentIntermittent Explosive Disorder1
2CompletedTreatmentMajor Depressive Disorder (MDD)1
2CompletedTreatmentMajor Depressive Disorder (MDD) / Unipolar Depression1
2CompletedTreatmentMenopausal and Postmenopausal Disorders / Moderate Depression1
2CompletedTreatmentMotor Impairments / Stroke, Ischemic1
2CompletedTreatmentPulmonary Arterial Hypertension (PAH)1
2CompletedTreatmentSevere Mood Dysregulation1
2Not Yet RecruitingTreatmentBrain Diseases / Brain Infarction / Central Nervous System Diseases / Cerebral Infarctions / Cerebrovascular Accidents / Cerebrovascular Disorders / Ischemia, Brain / Nervous System Diseases / Strokes / Vascular Diseases1
2RecruitingPreventionEpilepsies / Sudden unexplained death in epilepsy1
2RecruitingTreatmentMotor Function / Strokes1
2RecruitingTreatmentStroke, Acute / Visual Field Loss1
2TerminatedTreatmentMajor Depressive Disorder (MDD)1
2TerminatedTreatmentObsessive-Compulsive Disorder (OCD)1
2WithdrawnTreatmentAutism, Early Infantile1
2WithdrawnTreatmentSevere Stroke With Affected Arm Motor Function1
2, 3CompletedTreatmentDepression1
2, 3CompletedTreatmentDepression / Suicide, Attempted1
2, 3CompletedTreatmentNon-erosive Reflux Disease (NERD)1
3CompletedTreatmentAnxiety Disorders1
3CompletedTreatmentAutistic Disorder1
3CompletedTreatmentDepression1
3CompletedTreatmentDepression / Major Depressive Disorder (MDD)1
3CompletedTreatmentDepression / Major Depressive Disorder (MDD) / Nicotine Dependence1
3CompletedTreatmentDepression / Smoking1
3CompletedTreatmentEpilepsies / Ictal/Post-ictal Hypoxemia1
3CompletedTreatmentFibromyalgia / Juvenile Primary Fibromyalgia Syndrome (JPFS)1
3CompletedTreatmentMajor Depressive Disorder (MDD)8
3CompletedTreatmentSocial Phobia1
3CompletedTreatmentStress Disorders, Post-Traumatic1
3CompletedTreatmentTreatment Resistant Depression (TRD)1
3RecruitingTreatmentMajor Depressive Disorder (MDD)5
3RecruitingTreatmentPersonality Disorders / Psychotic Disorder NOS1
3RecruitingTreatmentPremenstrual Syndrome3
3RecruitingTreatmentStrokes1
3TerminatedSupportive CareIntracerebral Hemorrhage / Motor Impairments1
3TerminatedTreatmentAnxiety Disorders / Dementias / Depression / Psychosomatic Disorders / Schizophrenic Disorders1
3TerminatedTreatmentAutistic Disorder1
3TerminatedTreatmentBipolar Disorder (BD) / Depression1
3TerminatedTreatmentTreatment Resistant Depression (TRD)1
4CompletedBasic ScienceMajor Depressive Disorder (MDD)1
4CompletedDiagnosticMajor Depressive Disorder (MDD)1
4CompletedHealth Services ResearchHealthy Volunteers1
4CompletedHealth Services ResearchObsessive Compulsive Disorder (OCD)1
4CompletedOtherHealthy Controls / Major Depressive Disorder (MDD)1
4CompletedTreatmentAlcohol Dependence / Alcoholism / Depression1
4CompletedTreatmentAlcohol-Related Disorders / Marijuana Abuse / Substance-Related Disorders1
4CompletedTreatmentAnorexia Nervosa (AN) / Eating Disorders1
4CompletedTreatmentAnxiety Disorders / Moods Disorders / Schizophrenic Disorders1
4CompletedTreatmentBipolar Disorder (BD)4
4CompletedTreatmentBipolar Disorder (BD) / Depression1
4CompletedTreatmentBody Dysmorphic Disorders1
4CompletedTreatmentBorderline Personality Disorder (BPD)1
4CompletedTreatmentDepression1
4CompletedTreatmentDepression, Bipolar2
4CompletedTreatmentDepression / Menopause1
4CompletedTreatmentDepression / Sleep Initiation and Maintenance Disorders1
4CompletedTreatmentDepressive Disorder NOS / Dysthymic Disorder / Major Depressive Disorder (MDD)1
4CompletedTreatmentMajor Depressive Disorder (MDD)6
4CompletedTreatmentObsessive Compulsive Disorder (OCD)1
4CompletedTreatmentObsessive-Compulsive Disorder (OCD)1
4CompletedTreatmentPremenstrual Dysphoric Disorder / Premenstrual Syndrome1
4CompletedTreatmentPsychotic Disorder NOS1
4RecruitingNot AvailableDepressive Disorders / Lactation1
4RecruitingBasic ScienceBipolar Disorder (BD)1
4RecruitingDiagnosticFragile X Syndrome (FXS) / Velocardiofacial Syndrome / Williams Syndrome1
4RecruitingOtherAttenuated Psychosis Syndrome1
4RecruitingTreatmentAnxiety Disorders / Obsessive-Compulsive Disorder (OCD) / Psychiatric Disorder NOS1
4RecruitingTreatmentBulimia Nervosa (BN)1
4RecruitingTreatmentDepression / Hemodialysis-Induced Symptom1
4RecruitingTreatmentDepressive Disorders1
4RecruitingTreatmentStrokes1
4TerminatedPreventionDepression1
4TerminatedTreatmentDepression1
4TerminatedTreatmentDepression / Relapsing Remitting Multiple Sclerosis (RRMS)1
4TerminatedTreatmentEnd Stage Renal Disease (ESRD) / Major Depressive Disorder (MDD)1
4TerminatedTreatmentPediatric Bipolar Disorder / Pediatric OCD1
4Unknown StatusTreatmentAlcoholism / Depression / Suicidal Behaviour1
4Unknown StatusTreatmentAntidepressive Agents / Fluoxetine / Major Depressive Disorder (MDD) / Pharmacogenetics / Venlafaxine1
4Unknown StatusTreatmentBorderline Personality Disorder (BPD) / Suicide1
4Unknown StatusTreatmentMajor Depressive Disorder (MDD)3
4Unknown StatusTreatmentPosttraumatic Stress Disorder, Combat-related1
4WithdrawnTreatmentDepression1
Not AvailableActive Not RecruitingNot AvailableAnxiety Disorders / Generalized Anxiety Disorder (GAD) / Obsessive-Compulsive Disorder (OCD) / Panic Disorders / Post-Traumatic Stress Disorder (PTSD) / Social Anxiety Disorder (SAD)1
Not AvailableActive Not RecruitingNot AvailableMajor Depressive Disorder (MDD)1
Not AvailableActive Not RecruitingDiagnosticGeneralized Anxiety Disorder (GAD) / Separation Anxiety Disorder / Social Phobia1
Not AvailableActive Not RecruitingTreatmentDepression1
Not AvailableCompletedNot AvailableAcute Kidney Injury (AKI) / Depression1
Not AvailableCompletedNot AvailableDiabetes, Diabetes Mellitus Type 11
Not AvailableCompletedNot AvailableHealthy Volunteers2
Not AvailableCompletedBasic ScienceAnorexia Nervosa (AN)1
Not AvailableCompletedBasic ScienceDrug-Drug Interaction (DDI) / Healthy Volunteers1
Not AvailableCompletedBasic ScienceMajor Depressive Disorder (MDD)2
Not AvailableCompletedOtherDepression1
Not AvailableCompletedPreventionBipolar Disorder (BD) / Depression / Psychotic Disorder NOS / Schizophrenic Disorders1
Not AvailableCompletedPreventionCardiovascular Disease (CVD) / Heart Diseases1
Not AvailableCompletedPreventionDepression1
Not AvailableCompletedSupportive CareIctal Hypoventilation / Uncontrolled Partial Epilepsy1
Not AvailableCompletedTreatmentAutism, Early Infantile1
Not AvailableCompletedTreatmentAutistic Disorder1
Not AvailableCompletedTreatmentBulimia Nervosa (BN)1
Not AvailableCompletedTreatmentCancer, Advanced1
Not AvailableCompletedTreatmentCocaine-Related Disorders / Opioid-Related Disorders1
Not AvailableCompletedTreatmentDepersonalization Disorder1
Not AvailableCompletedTreatmentDepression3
Not AvailableCompletedTreatmentDepression / Major Depressive Disorder (MDD)1
Not AvailableCompletedTreatmentDepression / Strokes1
Not AvailableCompletedTreatmentEating Disorders1
Not AvailableCompletedTreatmentMajor Depressive Disorder (MDD)3
Not AvailableCompletedTreatmentObsessive-Compulsive Disorder (OCD)1
Not AvailableCompletedTreatmentPremenstrual Syndrome1
Not AvailableEnrolling by InvitationNot AvailableBipolar Disorder (BD)1
Not AvailableEnrolling by InvitationTreatmentMenopausal Hot Flushes / Quality of Life1
Not AvailableNot Yet RecruitingHealth Services ResearchUnipolar Depression1
Not AvailableNot Yet RecruitingTreatmentFeeding and Eating Disorders1
Not AvailableNot Yet RecruitingTreatmentObsessive Compulsive Disorder (OCD)1
Not AvailableRecruitingOtherObsessive-Compulsive Disorder (OCD)1
Not AvailableRecruitingTreatmentAlcohol-Related Disorders / Brain Injury / Depression / Disease, Chronic / Mild Cognitive Impairment (MCI) / Pain / Posttraumatic Stress Disorders / Quality of Life / Substance-Related Disorders / Suicidal Ideation / Wounds and Injuries1
Not AvailableRecruitingTreatmentGeneralized Anxiety Disorder (GAD)1
Not AvailableRecruitingTreatmentPost-stroke Depression1
Not AvailableTerminatedTreatmentAdolescent Depression1
Not AvailableTerminatedTreatmentCerebral Infarctions1
Not AvailableTerminatedTreatmentMajor Depressive Disorder (MDD)1
Not AvailableUnknown StatusTreatmentDepression1
Not AvailableUnknown StatusTreatmentMajor Depressive Disorder (MDD)1
Not AvailableUnknown StatusTreatmentTreatment Resistant Depression (TRD)1
Not AvailableWithdrawnNot AvailableDepression1
Not AvailableWithdrawnTreatmentPsychotic Disorder NOS1
Not AvailableWithdrawnTreatmentStrokes1

Pharmacoeconomics

Manufacturers
  • Barr laboratories inc
  • Dr reddys laboratories ltd
  • Eli lilly and co
  • Mutual pharmacal co
  • Watson laboratories inc
  • Alembic ltd
  • Alphapharm party ltd
  • Aurobindo pharma ltd
  • Beijing double crane pharmaceutical co ltd
  • Carlsbad technology inc
  • Dr reddys laboratories inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Landela pharmaceutical
  • Mallinckrodt inc
  • Mylan pharmaceuticals inc
  • Par pharmaceutical inc
  • Pliva inc
  • Ranbaxy laboratories ltd
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Wockhardt ltd
  • Lilly research laboratories div eli lilly and co
  • Actavis mid atlantic llc
  • Aurobindo pharma usa inc
  • Hi tech pharmacal co inc
  • Lannett holdings inc
  • Novex pharma
  • Pharmaceutical assoc inc div beach products
  • Silarx pharmaceuticals inc
  • Wockhardt eu operations (swiss) ag
  • Warner chilcott inc
Packagers
  • Advanced Pharmaceutical Services Inc.
  • Alphapharm Party Ltd.
  • Amerisource Health Services Corp.
  • Amneal Pharmaceuticals
  • Apotex Inc.
  • AQ Pharmaceuticals Inc.
  • A-S Medication Solutions LLC
  • Atlantic Biologicals Corporation
  • Aurobindo Pharma Ltd.
  • Barr Pharmaceuticals
  • Blenheim Pharmacal
  • Bryant Ranch Prepack
  • Cardinal Health
  • Caremark LLC
  • Carlsbad Technology Inc.
  • Comprehensive Consultant Services Inc.
  • Corepharma LLC
  • Coupler Enterprises Inc.
  • D.M. Graham Laboratories Inc.
  • DHHS Program Support Center Supply Service Center
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Doctor Reddys Laboratories Ltd.
  • DSM Corp.
  • Eli Lilly & Co.
  • Eon Labs
  • Golden State Medical Supply Inc.
  • H.J. Harkins Co. Inc.
  • Heartland Repack Services LLC
  • Innoviant Pharmacy Inc.
  • Ivax Pharmaceuticals
  • Kaiser Foundation Hospital
  • Keltman Pharmaceuticals Inc.
  • Lake Erie Medical and Surgical Supply
  • Legacy Pharmaceuticals Packaging LLC
  • Liberty Pharmaceuticals
  • Lilly Del Caribe Inc.
  • Major Pharmaceuticals
  • Mallinckrodt Inc.
  • Medvantx Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Northstar Rx LLC
  • Norwich Pharmaceuticals Inc.
  • Novex Pharma
  • Novopharm Ltd.
  • Nucare Pharmaceuticals Inc.
  • Ohm Laboratories Inc.
  • Palmetto Pharmaceuticals Inc.
  • Par Pharmaceuticals
  • PCA LLC
  • PD-Rx Pharmaceuticals Inc.
  • Pharmaceutical Association
  • Pharmaceutical Utilization Management Program VA Inc.
  • Pharmedix
  • Pharmpak Inc.
  • Physician Partners Ltd.
  • Physicians Total Care Inc.
  • Pliva Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepackage Specialists
  • Prepak Systems Inc.
  • Promex Medical Inc.
  • Prx Pharmaceuticals
  • Ranbaxy Laboratories
  • Rebel Distributors Corp.
  • Remedy Repack
  • Resource Optimization and Innovation LLC
  • Sandhills Packaging Inc.
  • Sandoz
  • Silarx Pharmaceuticals
  • Southwood Pharmaceuticals
  • Spectrum Pharmaceuticals
  • St Mary's Medical Park Pharmacy
  • Stat Rx Usa
  • Teva Pharmaceutical Industries Ltd.
  • Tya Pharmaceuticals
  • UDL Laboratories
  • Va Cmop Dallas
  • Vangard Labs Inc.
  • Warner Chilcott Co. Inc.
  • WC Pharmaceuticals
  • Wockhardt Ltd.
  • Xactdose Inc.
Dosage forms
FormRouteStrength
CapsuleOral20 mg/1
CapsuleOral40 mg/1
LiquidOral20 mg/5mL
SolutionOral20 mg/5mL
TabletOral60 mg/1
Tablet, film coatedOral60 mg/1
CapsuleOral10 mg/1
Capsule, delayed release pelletsOral90 mg/1
TabletOral10 mg/1
TabletOral20 mg/1
Tablet, coatedOral10 mg/1
Tablet, coatedOral20 mg/1
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral20 mg/1
CapsuleOral40 mg
Kit
SolutionOral20 mg
CapsuleOral
CapsuleOral60 mg
CapsuleOral20 mg
CapsuleOral10 mg
LiquidOral20 mg
Capsule, delayed releaseOral90 mg/1
Prices
Unit descriptionCostUnit
PROzac 20 mg/5ml Solution 120ml Bottle266.51USD bottle
PROzac Weekly 1 Package = 4 capsule (90 mg) Disp Pack140.77USD disp
Sarafem 7 10 mg tablet Box61.08USD box
Sarafem 7 20 mg tablet Each Box Contains 7 tablet59.55USD box
Prozac weekly 90 mg capsule34.5USD capsule
PROzac 40 mg capsule13.89USD capsule
Fluoxetine hcl powder8.32USD g
Sarafem 10 mg tablet7.91USD tablet
Sarafem 15 mg tablet7.91USD tablet
Sarafem 20 mg tablet7.91USD tablet
PROzac 20 mg capsule6.95USD capsule
PROzac 10 mg capsule6.77USD capsule
FLUoxetine HCl 40 mg capsule5.54USD capsule
PROzac 10 mg tablet4.31USD tablet
Fluoxetine hcl 20 mg tablet4.26USD tablet
Rapiflux 20 mg tablet3.11USD tablet
FLUoxetine HCl 20 mg capsule2.77USD capsule
Fluoxetine hcl 10 mg tablet2.72USD tablet
FLUoxetine HCl 10 mg capsule2.7USD capsule
Fxt 40 40 mg Capsule2.3USD capsule
Prozac 10 mg Capsule2.02USD capsule
Prozac 20 mg Capsule2.02USD capsule
Apo-Fluoxetine 10 mg Capsule1.13USD capsule
Co Fluoxetine 10 mg Capsule1.13USD capsule
Mylan-Fluoxetine 10 mg Capsule1.13USD capsule
Novo-Fluoxetine 10 mg Capsule1.13USD capsule
Nu-Fluoxetine 10 mg Capsule1.13USD capsule
Phl-Fluoxetine 10 mg Capsule1.13USD capsule
Pms-Fluoxetine 10 mg Capsule1.13USD capsule
Ratio-Fluoxetine Hydrochloride 10 mg Capsule1.13USD capsule
Sandoz Fluoxetine 10 mg Capsule1.13USD capsule
Apo-Fluoxetine 20 mg Capsule1.06USD capsule
Co Fluoxetine 20 mg Capsule1.06USD capsule
Mylan-Fluoxetine 20 mg Capsule1.06USD capsule
Novo-Fluoxetine 20 mg Capsule1.06USD capsule
Nu-Fluoxetine 20 mg Capsule1.06USD capsule
Phl-Fluoxetine 20 mg Capsule1.06USD capsule
Pms-Fluoxetine 20 mg Capsule1.06USD capsule
Ratio-Fluoxetine Hydrochloride 20 mg Capsule1.06USD capsule
Sandoz Fluoxetine 20 mg Capsule1.06USD capsule
FLUoxetine HCl 20 mg/5ml Solution1.03USD ml
Apo-Fluoxetine 4 mg/ml Liquid0.61USD liquid
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6960577No1997-11-012017-11-01Us
US5910319Yes1997-11-292017-11-29Us
US5985322Yes1997-11-292017-11-29Us
USRE39030No1997-05-292017-05-29Us
US5945416No1997-03-242017-03-24Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)179-182 °CNot Available
water solubility50 mg/mL at 25 °CNot Available
logP4.05ADLARD,M ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0017 mg/mLALOGPS
logP4.09ALOGPS
logP4.17ChemAxon
logS-5.3ALOGPS
pKa (Strongest Basic)9.8ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area21.26 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity80.37 m3·mol-1ChemAxon
Polarizability30.33 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.983
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.5899
P-glycoprotein inhibitor IInhibitor0.8565
P-glycoprotein inhibitor IIInhibitor0.5459
Renal organic cation transporterInhibitor0.5633
CYP450 2C9 substrateNon-substrate0.7475
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.5754
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorInhibitor0.8993
CYP450 3A4 inhibitorInhibitor0.7959
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7149
Ames testNon AMES toxic0.7105
CarcinogenicityNon-carcinogens0.8089
BiodegradationNot ready biodegradable0.9868
Rat acute toxicity2.6048 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.6058
hERG inhibition (predictor II)Inhibitor0.8467
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-0006-9200000000-dcf68dbfd090c7fdfe11
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03di-0009000000-ed61090013f0dc5f5c5a
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014i-0190000000-e9bcd2accdf5b7e40a88
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014i-0590000000-04b1d4265cb156217f40
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014i-0790000000-5c42b9a9a2cd0c4114aa
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0gb9-0960000000-88822d2fb3e7c0cdc0b3
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0900000000-6b560941c92823b7901c
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-0109000000-1531c1e1630dcb42b497
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0006-9000000000-53199cfe3b343ae81afd
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-0109000000-0e790a7e6032e51bfeb3
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00kf-9800000000-64d39c4a4fcc7f8b6f47
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00kf-9700000000-e516356ce3eca65bece8
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0900000000-6b560941c92823b7901c
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0zgi-1390000000-84c6bc70aefcd3758f31
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0f7o-6940000000-a424e26ecc7465229968
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4m-0390000000-9b7253cd5718aa434e46
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4m-0290000000-d88f8004205c7223aa9f
MS/MS Spectrum - , positiveLC-MS/MSsplash10-01t9-0592000000-92a48c620c961fdb430f
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-0409000000-03f5678c6178e634f254
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014l-4900000000-2940e7bc3f6a559e61fc
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014l-5900000000-c904d50adb4d1ea90abd
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014l-5900000000-5cbc74ddfe414085c9bd
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0002-0900000000-6b560941c92823b7901c
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0002-0900000000-f5f65bd85fe3483260bb

Taxonomy

Description
This compound belongs to the class of organic compounds known as trifluoromethylbenzenes. These are organofluorine compounds that contain a benzene ring substituted with one or more trifluoromethyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Trifluoromethylbenzenes
Direct Parent
Trifluoromethylbenzenes
Alternative Parents
Phenoxy compounds / Phenol ethers / Aralkylamines / Alkyl aryl ethers / Dialkylamines / Organopnictogen compounds / Organofluorides / Hydrocarbon derivatives / Alkyl fluorides
Substituents
Trifluoromethylbenzene / Phenoxy compound / Phenol ether / Alkyl aryl ether / Aralkylamine / Secondary aliphatic amine / Ether / Secondary amine / Organic oxygen compound / Organooxygen compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
aromatic ether, secondary amino compound, (trifluoromethyl)benzenes (CHEBI:86990)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serotonin:sodium symporter activity
Specific Function
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into t...
Gene Name
SLC6A4
Uniprot ID
P31645
Uniprot Name
Sodium-dependent serotonin transporter
Molecular Weight
70324.165 Da
References
  1. Richman A, Heinrichs SC: Seizure prophylaxis in an animal model of epilepsy by dietary fluoxetine supplementation. Epilepsy Res. 2007 Apr;74(1):19-27. Epub 2007 Jan 9. [PubMed:17215106]
  2. Iceta R, Mesonero JE, Alcalde AI: Effect of long-term fluoxetine treatment on the human serotonin transporter in Caco-2 cells. Life Sci. 2007 Mar 27;80(16):1517-24. Epub 2007 Jan 20. [PubMed:17289086]
  3. Mirza NR, Nielsen EO, Troelsen KB: Serotonin transporter density and anxiolytic-like effects of antidepressants in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2007 May 9;31(4):858-66. Epub 2007 Jan 30. [PubMed:17335951]
  4. Sanders AC, Hussain AJ, Hen R, Zhuang X: Chronic blockade or constitutive deletion of the serotonin transporter reduces operant responding for food reward. Neuropsychopharmacology. 2007 Nov;32(11):2321-9. Epub 2007 Mar 14. [PubMed:17356573]
  5. Goren MZ, Kucukibrahimoglu E, Berkman K, Terzioglu B: Fluoxetine partly exerts its actions through GABA: a neurochemical evidence. Neurochem Res. 2007 Sep;32(9):1559-65. Epub 2007 May 8. [PubMed:17486443]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  7. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the ...
Gene Name
KCNH2
Uniprot ID
Q12809
Uniprot Name
Potassium voltage-gated channel subfamily H member 2
Molecular Weight
126653.52 Da
References
  1. Chiu PJ, Marcoe KF, Bounds SE, Lin CH, Feng JJ, Lin A, Cheng FC, Crumb WJ, Mitchell R: Validation of a [3H]astemizole binding assay in HEK293 cells expressing HERG K+ channels. J Pharmacol Sci. 2004 Jul;95(3):311-9. [PubMed:15272206]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...
Gene Name
HTR2C
Uniprot ID
P28335
Uniprot Name
5-hydroxytryptamine receptor 2C
Molecular Weight
51820.705 Da
References
  1. Chanrion B, Mannoury la Cour C, Gavarini S, Seimandi M, Vincent L, Pujol JF, Bockaert J, Marin P, Millan MJ: Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulation of cell surface expression and signal transduction. Mol Pharmacol. 2008 Mar;73(3):748-57. Epub 2007 Dec 14. [PubMed:18083778]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Cyclin-dependent protein serine/threonine kinase regulator activity
Specific Function
Binds to the catalytic subunit of the cyclin dependent kinases and is essential for their biological function.
Gene Name
CKS1B
Uniprot ID
P61024
Uniprot Name
Cyclin-dependent kinases regulatory subunit 1
Molecular Weight
9660.14 Da
References
  1. Krishnan A, Hariharan R, Nair SA, Pillai MR: Fluoxetine mediates G0/G1 arrest by inducing functional inhibition of cyclin dependent kinase subunit (CKS)1. Biochem Pharmacol. 2008 May 15;75(10):1924-34. doi: 10.1016/j.bcp.2008.02.013. Epub 2008 Feb 17. [PubMed:18371935]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Drug binding
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name
CHRNA2
Uniprot ID
Q15822
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-2
Molecular Weight
59764.82 Da
References
  1. Garcia-Colunga J, Awad JN, Miledi R: Blockage of muscle and neuronal nicotinic acetylcholine receptors by fluoxetine (Prozac). Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):2041-4. [PubMed:9050901]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Ligand-gated ion channel activity
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name
CHRNA3
Uniprot ID
P32297
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-3
Molecular Weight
57479.54 Da
References
  1. Garcia-Colunga J, Awad JN, Miledi R: Blockage of muscle and neuronal nicotinic acetylcholine receptors by fluoxetine (Prozac). Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):2041-4. [PubMed:9050901]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Ligand-gated ion channel activity
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name
CHRNB4
Uniprot ID
P30926
Uniprot Name
Neuronal acetylcholine receptor subunit beta-4
Molecular Weight
56378.985 Da
References
  1. Garcia-Colunga J, Awad JN, Miledi R: Blockage of muscle and neuronal nicotinic acetylcholine receptors by fluoxetine (Prozac). Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):2041-4. [PubMed:9050901]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Urichuk L, Prior TI, Dursun S, Baker G: Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008 Jun;9(5):410-8. [PubMed:18537577]
  2. Baumann P: Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996 Dec;31(6):444-69. [PubMed:8968657]
  3. Micallef J, Fakra E, Blin O: [Use of antidepressant drugs in schizophrenic patients with depression]. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. [PubMed:16910628]
  4. Rasmussen BB, Brosen K: Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit. 2000 Apr;22(2):143-54. [PubMed:10774624]
  5. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  6. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  7. Margolis JM, O'Donnell JP, Mankowski DC, Ekins S, Obach RS: (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metab Dispos. 2000 Oct;28(10):1187-91. [PubMed:10997938]
  8. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Micallef J, Fakra E, Blin O: [Use of antidepressant drugs in schizophrenic patients with depression]. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. [PubMed:16910628]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  4. Margolis JM, O'Donnell JP, Mankowski DC, Ekins S, Obach RS: (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metab Dispos. 2000 Oct;28(10):1187-91. [PubMed:10997938]
  5. von Moltke LL, Greenblatt DJ, Duan SX, Schmider J, Wright CE, Harmatz JS, Shader RI: Human cytochromes mediating N-demethylation of fluoxetine in vitro. Psychopharmacology (Berl). 1997 Aug;132(4):402-7. [PubMed:9298519]
  6. Wang JF, Yan JY, Wei DQ, Chou KC: Binding of CYP2C9 with diverse drugs and its implications for metabolic mechanism. Med Chem. 2009 May;5(3):263-70. [PubMed:19442216]
  7. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Not Available
Gene Name
CYP2B
Uniprot ID
Q14097
Uniprot Name
CYP2B protein
Molecular Weight
43147.81 Da
References
  1. Haduch A, Wojcikowski J, Daniel WA: Effect of selected antidepressant drugs on cytochrome P450 2B (CYP2B) in rat liver. An in vitro and in vivo study. Pharmacol Rep. 2008 Nov-Dec;60(6):957-65. [PubMed:19211989]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Micallef J, Fakra E, Blin O: [Use of antidepressant drugs in schizophrenic patients with depression]. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. [PubMed:16910628]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Micallef J, Fakra E, Blin O: [Use of antidepressant drugs in schizophrenic patients with depression]. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. [PubMed:16910628]
  2. DeVane CL, Donovan JL, Liston HL, Markowitz JS, Cheng KT, Risch SC, Willard L: Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers. J Clin Psychopharmacol. 2004 Feb;24(1):4-10. [PubMed:14709940]
  3. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  5. Margolis JM, O'Donnell JP, Mankowski DC, Ekins S, Obach RS: (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metab Dispos. 2000 Oct;28(10):1187-91. [PubMed:10997938]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Margolis JM, O'Donnell JP, Mankowski DC, Ekins S, Obach RS: (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metab Dispos. 2000 Oct;28(10):1187-91. [PubMed:10997938]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Margolis JM, O'Donnell JP, Mankowski DC, Ekins S, Obach RS: (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metab Dispos. 2000 Oct;28(10):1187-91. [PubMed:10997938]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Not Available
Specific Function
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in...
Gene Name
ORM1
Uniprot ID
P02763
Uniprot Name
Alpha-1-acid glycoprotein 1
Molecular Weight
23511.38 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE: Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther. 2003 Apr;305(1):197-204. [PubMed:12649369]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 11:06